

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199749853 B2**
(10) Patent No. **733964**

(54) Title
Novel flt-3 receptor agonists

(51)⁶ International Patent Classification(s)
C12N 015/12 C07K 014/475
A61K 038/18 C07K 016/22
A61K 048/00

(21) Application No: **199749853** (22) Application Date: **1997.10.23**

(87) WIPO No: **WO98/18923**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/030094	1996.10.25	US

(43) Publication Date : **1998.05.22**

(43) Publication Journal Date : **1998.07.16**

(44) Accepted Journal Date : **2001.05.31**

(71) Applicant(s)
G. D. Searle and Co.

(72) Inventor(s)
Charles A. McWherter; Yiqing Feng; John P. McKearn; Nicholas R. Staten; Philip R. streeter ; Susan L. Woulfe; Nancy I. Minster; John C. Minnerly

(74) Agent/Attorney
E F WELLINGTON and CO,312 St Kilda Road,MELBOURNE VIC 3006

(56) Related Art
AU 73844/96

OPI DATE 22/05/98 APPLN. ID 49853/97
AOJP DATE 16/07/98 PCT NUMBER PCT/US97/18700



AU9749853

(T)

(51) International Patent Classification⁶ : C12N 15/12, C07K 14/475, 16/22, A61K 38/18, 48/00		A1	(11) International Publication Number: WO 98/18923
			(43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/18700		(74) Agent: G.D. SEARLE & CO.; P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(22) International Filing Date: 23 October 1997 (23.10.97)			
(30) Priority Data: 60/030,094 25 October 1996 (25.10.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): MCWHERTER, Charles, A. [US/US]; 16564 Thunderhead Canyon Court, Wildwood, MO 63011 (US). FENG, Yiqing [US/US]; 423 Mission Court, St. Louis, MO 63130 (US). McKEARN, John, P. [US/US]; 18612 Babler Meadows Drive, St. Louis, MO 63038 (US). STATEN, Nicholas, R. [US/US]; 859 Queen Ann Place, St. Louis, MO 63122 (US). STREETER, Philip, R. [US/US]; 1555 Pond Road, Glencoe, MO 63038 (US). WOULFE, Susan, L. [US/US]; 1719 Woodmore Oaks Drive, Ballwin, MO 63021 (US). MINSTER, Nancy, I. [US/US]; 16080 Clarkson Woods, Chesterfield, MO 63017 (US). MINNERLY, John, C. [US/US]; 5824 Bristlecone Court, St. Louis, MO 63129 (US).			
(54) Title: NOVEL flt-3 RECEPTOR AGONISTS			
(57) Abstract Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.			

NOVEL flt3 RECEPTOR AGONISTS

The present application claims priority under Title 35, United States Code, §119 of United States Provisional application Serial No. 60/030,094, filed October 25, 1996.

FIELD OF THE INVENTION

10 The present invention relates to human flt3 receptor agonists. These flt3 receptor agonists retain one or more activities of native flt3 ligand and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may
15 include reduction of undesirable biological activities associated with native flt3 ligand and/or have improved physical properties which may include increased solubility, stability and refold efficiency.

BACKGROUND OF THE INVENTION

20 Colony stimulating factors which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of
25 hematopoietic stem cell-derived cells. Colony stimulating factors in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro
30 formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. Certain factors such
35 as flt3 ligand are able to predominately affect stem cells.

Tyrosine kinase receptors are growth factor receptors that regulate the proliferation and differentiation of a number of cell. Certain tyrosine kinase receptors function within the hematopoietic system. Flt3 ligand (Rosnet et al., *Oncogene*, 6:1641-1650, 1991) and flk-2 (Matthews et al., *Cell*, 65:1143-1152, 1991) are forms of a tyrosine kinase receptor that is related to c-fms and c-kit receptors. The flk-2 and flt3 receptors are similar in amino acid sequence and vary at two amino acid residues in the extracellular domain and diverge in a 31 amino acid segment located near the C-terminus.

flt3 ligand is a hematopoietic growth factor which has the property of being able to regulate the growth and differentiation of hematopoietic progenitor and stem cells. Because of its ability to support the growth and proliferation of progenitor cells, flt3 receptor agonists have potential for therapeutic use in treating hematopoietic disorders such as aplastic anemia and myelodysplastic syndromes. Additionally, flt3 receptor agonists will be useful in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic treatments such as radiation and chemotherapy.

WO 94/28391 discloses the native flt3 ligand protein sequence and a cDNA sequence encoding the flt3 ligand, methods of expressing flt3 ligand in a host cell transfected with the cDNA and methods of treating patients with a hematopoietic disorder using flt3 ligand.

US Patent No. 5,554,512 is directed to human flt3 ligand as an isolated protein, DNA encoding the flt3 ligand, host cells transfected with cDNAs encoding flt3

ligand and methods for treating patients with flt3 ligand.

- WO 94/26891 provides mammalian flt3 ligands,
5 including an isolate that has an insertion of 29 amino acids, and fragments thereof.

Rearrangement of Protein Sequences

- 10 In evolution, rearrangements of DNA sequences serve an important role in generating a diversity of protein structure and function. Gene duplication and exon shuffling provide an important mechanism to rapidly generate diversity and thereby provide organisms with a
15 competitive advantage, especially since the basal mutation rate is low (Doolittle, *Protein Science* 1:191-200, 1992).

- The development of recombinant DNA methods has made it possible to study the effects of sequence
20 transposition on protein folding, structure and function. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al., *Proc. Natl. Acad. Sci. U.S.A.* 76:3218-3222, 1979; Teather & Erfle, *J. Bacteriol.* 172: 3837-3841, 1990; Schimming et al., *Eur. J. Biochem.* 204: 13-19, 1992; Yamiuchi and Minamikawa, *FEBS Lett.* 260:127-130, 1991; MacGregor et al., *FEBS Lett.* 378:263-266, 1996). The first in vitro
25 application of this type of rearrangement to proteins was described by Goldenberg and Creighton (*J. Mol. Biol.* 165:407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the
30 original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this
35 point the new sequence is joined, either directly or

through an additional portion of sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new C-terminus of the chain.

This approach has been applied to proteins which range in size from 58 to 462 amino acids (Goldenberg & Creighton, *J. Mol. Biol.* **165**:407-413, 1983; Li & Coffino, *Mol. Cell. Biol.* **13**:2377-2383, 1993). The proteins examined have represented a broad range of structural classes, including proteins that contain predominantly α -helix (interleukin-4; Kreitman et al., *Cytokine* **7**:311-318, 1995), β -sheet (interleukin-1; Horlick et al., *Protein Eng.* **5**:427-431, 1992), or mixtures of the two (yeast phosphoribosyl anthranilate isomerase; Luger et al., *Science* **243**:206-210, 1989). Broad categories of protein function are represented in these sequence reorganization studies:

Enzymes

25	T4 lysozyme	Zhang et al., <i>Biochemistry</i> 32 :12311-12318 (1993); Zhang et al., <i>Nature Struct. Biol.</i> 1 :434-438 (1995)
30	dihydrofolate reductase	Buchwalder et al., <i>Biochemistry</i> 31 :1621-1630 (1994); Protasova et al., <i>Prot. Eng.</i> 7 :1373-1377 (1995)
35	ribonuclease T1	Mullins et al., <i>J. Am. Chem. Soc.</i> 116 :5529-5533 (1994); Garrett et al., <i>Protein Science</i> 5 :204-211 (1996)

- Bacillus* β -glucanase Hahn et al., *Proc. Natl. Acad. Sci. U.S.A.* **91**:10417-10421 (1994)
- 5 aspartate Yang & Schachman, *Proc. Natl. Acad. Sci. U.S.A.* **90**:11980-11984 (1993)
- transcarbamoylase
- phosphoribosyl Luger et al., *Science* **243**:206-210
anthranilate (1989); Luger et al., *Prot. Eng.*
isomerase **3**:249-258 (1990)
- 10 pepsin/pepsinogen Lin et al., *Protein Science* **4**:159-166 (1995)
- glyceraldehyde-3- Vignais et al., *Protein Science*
15 phosphate dehydro- **4**:994-1000 (1995)
genase
- ornithine Li & Coffino, *Mol. Cell. Biol.*
20 decarboxylase **13**:2377-2383 (1993)
- yeast Ritco-Vonsovici et al., *Biochemistry*
phosphoglycerate **34**:16543-16551 (1995)
dehydrogenase
- 25 **Enzyme Inhibitor**
- basic pancreatic Goldenberg & Creighton, *J. Mol. Biol.* **165**:407-413 (1983)
trypsin inhibitor
- 30 **Cytokines**
- interleukin-1 β Horlick et al., *Protein Eng.* **5**:427-431 (1992)
- 35 interleukin-4 Kreitman et al., *Cytokine* **7**:311-318 (1995)

**Tyrosine Kinase
Recognition Domain**

- 5 α -spectrin SH3 domain Viguera, et al., *J. Mol. Biol.* **247**:670-681 (1995)

**Transmembrane
Protein**

- 10 omp A Koebnik & Krämer, *J. Mol. Biol.* **250**:617-626 (1995)

Chimeric Protein

- 15 interleukin-4-*Pseudomonas* exotoxin fusion molecule Kreitman et al., *Proc. Natl. Acad. Sci. U.S.A.* **91**:6889-6893 (1994).

- 20 The results of these studies have been highly variable. In many cases substantially lower activity, solubility or thermodynamic stability were observed (*E. coli* dihydrofolate reductase, aspartate transcarbamoylase, phosphoribosyl anthranilate isomerase, glyceraldehyde-3-phosphate dehydrogenase, 25 ornithine decarboxylase, omp A, yeast phosphoglycerate dehydrogenase). In other cases, the sequence rearranged protein appeared to have many nearly identical properties as its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, ribonuclease T1, 30 *Bacillus* β -glucanase, interleukin-1 β , α -spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases, an unexpected improvement over some properties of the natural sequence was observed, e.g., the solubility and refolding rate for rearranged α -spectrin SH3 domain 35 sequences, and the receptor affinity and anti-tumor activity of transposed interleukin-4-*Pseudomonas* exotoxin fusion molecule (Kreitman et al., *Proc. Natl.*

Acad. Sci. U.S.A. **91**:6889-6893, 1994; Kreitman et al.,
Cancer Res. **55**:3357-3363, 1995).

The primary motivation for these types of studies
has been to study the role of short-range and long-range
5 interactions in protein folding and stability. Sequence
rearrangements of this type convert a subset of
interactions that are long-range in the original
sequence into short-range interactions in the new
sequence, and vice versa. The fact that many of these
10 sequence rearrangements are able to attain a
conformation with at least some activity is persuasive
evidence that protein folding occurs by multiple folding
pathways (Viguera, et al., *J. Mol. Biol.* **247**:670-681,
1995). In the case of the SH3 domain of α -spectrin,
15 choosing new termini at locations that corresponded to β
-hairpin turns resulted in proteins with slightly less
stability, but which were nevertheless able to fold.


The positions of the internal breakpoints used in
the studies cited here are found exclusively on the
20 surface of proteins, and are distributed throughout the
linear sequence without any obvious bias towards the
ends or the middle (the variation in the relative
distance from the original N-terminus to the breakpoint
is ca. 10 to 80% of the total sequence length). The
25 linkers connecting the original N- and C-termini in
these studies have ranged from 0 to 9 residues. In one
case (Yang & Schachman, *Proc. Natl. Acad. Sci. U.S.A.*
90:11980-11984, 1993), a portion of sequence has been
deleted from the original C-terminal segment, and the
30 connection made from the truncated C-terminus to the
original N-terminus. Flexible hydrophilic residues such
as Gly and Ser are frequently used in the linkers.
Viguera, et al. (*J. Mol. Biol.* **247**:670-681, 1995)
compared joining the original N- and C-termini with 3-
35 or 4-residue linkers; the 3-residue linker was less
thermodynamically stable. Protasova et al. (*Protein*
Eng. **7**:1373-1377, 1994) used 3- or 5-residue linkers in

connecting the original N-termini of *E. coli*
dihydrofolate reductase; only the 3-residue linker
produced protein in good yield.

5

Summary of the Invention

The modified human flt3 receptor agonists of the
 5 present invention can be represented by the Formula:



wherein;

- 10 a is 0 or 1;
 X^1 is a peptide comprising an amino acid
 sequence corresponding to the sequence of residues n+1
 through J;
 X^2 is a peptide comprising an amino acid
 15 sequence corresponding to the sequence of residues 1
 through n;
 n is an integer ranging from 1 to J-1; and
 L is a linker.

- 20 In the formula above the constituent amino acids
 residues of human flt3 ligand are numbered sequentially
 1 through J from the amino to the carboxyl terminus. A
 pair of adjacent amino acids within this protein may be
 numbered n and n+1 respectively where n is an integer
 25 ranging from 1 to J-1. The residue n+1 becomes the new
 N-terminus of the new flt3 receptor agonist and the
 residue n becomes the new C-terminus of the new flt3
 receptor agonist.

- 30 The present invention relates to novel flt3
 receptor agonists of the following formula:

	ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg	
	10	20
35	GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp	
	30	40
40	GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu	
	50	60

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis
 70 80
 5 PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn
 90 100
 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr
 110 120
 10 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuPro
 130 140
 ProProTrpSerProArgProLeuGluAlaThrAlaProThrAlaProGlnProProLeu
 150 160
 15 LeuLeuLeuLeuLeuLeuProValGlyLeuLeuLeuLeuAlaAlaAlaTrpCysLeuHis
 170 180
 20 TrpGlnArgThrArgArgArgThrProArgProGlyGluGlnValProProValProSer
 190 200
 ProGlnAspLeuLeuLeuValGluHis SEQ ID NO:145
 209

25 wherein the N-terminus is joined to the C-terminus
 directly or through a linker capable of joining the N-
 terminus to the C-terminus and having new C- and N-
 termini at amino acids;

30

28-29	42-43	93-94
29-30	64-65	94-95
30-31	65-66	95-96
31-32	66-67	96-97
32-33	86-87	97-98
34-35	87-88	98-99
36-37	88-89	99-100
37-38	89-90	100-101
38-39	90-91	101-102
39-40	91-92	102-103
40-41	92-93	respectively; and
41-42		

additionally said flt3 receptor agonist polypeptide can
 be immediately preceded by (methionine⁻¹), (alanine⁻¹) or
 (methionine⁻², alanine⁻¹).

35

A preferred embodiment is human flt3 receptor
 agonist polypeptide, comprising a modified flt3 ligand
 amino acid sequence of the Formula:

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg
 10 20
 5 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp
 30 40
 GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu
 50 60
 10 LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis
 70 80
 PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn
 15 90 100
 IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr
 110 120
 20 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu
 130
 SEQ ID NO:144

wherein the N-terminus is joined to the C-terminus
 directly or through a linker capable of joining the N-
 25 terminus to the C-terminus and having new C- and N-
 termini at amino acids;

28-29	42-43	93-94
29-30	64-65	94-95
30-31	65-66	95-96
31-32	66-67	96-97
32-33	86-87	97-98
34-35	87-88	98-99
36-37	88-89	99-100
37-38	89-90	100-101
38-39	90-91	101-102
39-40	91-92	102-103
40-41	92-93	respectively; and
41-42		

additionally said flt3 receptor agonist polypeptide can
 30 be immediately preceded by (methionine⁻¹), (alanine⁻¹) or
 (methionine⁻², alanine⁻¹).

The more preferred breakpoints at which new C-
 terminus and N-terminus can be made are 36-37, 37-38,
 35 38-39, 39-40, 40-41, 41-42, 42-43, 64-65, 65-66, 66-67,

86-87, 87-88, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94,
95,-96, 96-97, 97-98, 99-100 and 100-101

The most preferred breakpoints at which new C-
5 terminus and N-terminus can be made are; 39-40, 65-66,
89-90, 99-100 and 100-101.

The flt3 receptor agonists of the present invention
may contain amino acid substitutions, deletions and/or
10 insertions. It is also intended that the flt3 receptor
agonists of the present invention may also have amino
acid deletions at either/or both the N- and C- termini
of the original protein and or deletions from the new N-
and/or C-termini of the sequence rearranged proteins in
15 the formulas shown above.

The flt3 receptor agonists of the present invention
may contain amino acid substitutions, deletions and/or
insertions.

20

A preferred embodiment of the present invention the
linker (L) joining the N-terminus to the C-terminus is a
polypeptide selected from the group consisting of:

GlyGlyGlySer SEQ ID NO:38;
25 GlyGlyGlySerGlyGlyGlySer SEQ ID NO:39;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO:40;
SerGlyGlySerGlyGlySer SEQ ID NO:41;
GluPheGlyAsnMet SEQ ID NO:42;
GluPheGlyGlyAsnMet SEQ ID NO:43;
30 GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO:44;
GlyGlySerAspMetAlaGly SEQ ID NO:45;
SerGlyGlyAsnGly SEQ ID NO:46;
SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:47;
SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ
35 ID NO:48;
SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:49;

SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ
 ID NO:50;
 GlyGlyGlySerGlyGly SEQ ID NO:51;
 GlyGlyGlySerGlyGlyGly SEQ ID NO:52;
 5 GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:53;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID
 NO:54;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly SEQ
 ID NO:55;
 10 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly
 GlyGlySerGly SEQ ID NO:56;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly
 GlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:148;
 ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly
 15 GlnProProLeu SEQ ID NO:149;
 ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ
 ID NO:150; and
 ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer
 SEQ ID NO:151.

20

The present invention also encompasses recombinant
 human flt3 receptor agonists co-administered or
 sequentially with one or more additional colony
 stimulating factors (CSF) including, cytokines,
 25 lymphokines, interleukins, hematopoietic growth factors
 which include but are not limited to GM-CSF, G-CSF, c-
 mpl ligand (also known as TPO or MGDF), M-CSF,
 erythropoietin (FLT3), IL-1, IL-4, IL-2, IL-3, IL-5, IL-
 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15,
 30 LIF, human growth hormone, B-cell growth factor, B-cell
 differentiation factor, eosinophil differentiation
 factor and stem cell factor (SCF) also known as steel
 factor or c-kit ligand (herein collectively referred to
 as "factors"). These co-administered mixtures may be
 35 characterized by having the usual activity of both of
 the peptides or the mixture may be further characterized
 by having a biological or physiological activity greater

than simply the additive function of the presence of the
flt3 receptor agonists or the second colony stimulating
factor alone. The co-administration may also provide an
enhanced effect on the activity or an activity different
5 from that expected by the presence of the flt3 ligand or
the second colony stimulating factor. The co-
administration may also have an improved activity
profile which may include reduction of undesirable
biological activities associated with native human flt3
10 ligand. In addition to the list above, IL-3 variants
taught in WO 94/12639 and WO 94/12638 fusion protein
taught in WO 95/21197, and WO 95/21254 G-CSF receptor
agonists disclosed in WO 97/12977, c-mpl receptor
agonists disclosed in WO 97/12978, IL-3 receptor
15 agonists disclosed in WO 97/12979 and multi-functional
receptor agonists taught in WO 97/12985 can be co-
administered with the polypeptides of the present
invention. As used herein "IL-3 variants" refer to IL-3
variants taught in WO 94/12639 and WO 94/12638. As used
20 herein "fusion proteins" refer to fusion protein taught
in WO 95/21197, and WO 95/21254. As used herein "G-CSF
receptor agonists" refer to G-CSF receptor agonists
disclosed in WO 97/12978. As used herein "c-mpl receptor
agonists" refer to c-mpl receptor agonists disclosed in
25 WO 97/12978. As used herein "IL-3 receptor agonists"
refer to IL-3 receptor agonists disclosed in WO
97/12979. As used herein "multi-functional receptor
agonists" refer to multi-functional receptor agonists
taught in WO 97/12985.

30

In addition, it is envisioned that in vitro uses
would include the ability to stimulate bone marrow and
blood cell activation and growth before the expanded
35 cells are infused into patients. Another intended use is
for the production of dendritic cells both *in vivo* and
ex vivo.

Brief Description of the Figures

Figure 1 schematically illustrates the sequence
5 rearrangement of a protein. The N-terminus (N) and the
C-terminus (C) of the native protein are joined through
a linker, or joined directly. The protein is opened at a
breakpoint creating a new N-terminus (new N) and a new
C-terminus (new-C) resulting in a protein with a new
10 linear amino acid sequence. A rearranged molecule may be
synthesized de novo as linear molecule and not go
through the steps of joining the original N-terminus and
the C-terminus and opening of the protein at the
breakpoint.

15
Figure 2 shows a schematic of Method I, for
creating new proteins in which the original N-terminus
and C-terminus of the native protein are joined with a
linker and different N-terminus and C-terminus of the
20 protein are created. In the example shown the sequence
rearrangement results in a new gene encoding a protein
with a new N-terminus created at amino acid 97 of the
original protein, the original C-terminus (a.a. 174)
joined to the amino acid 11 (a.a. 1- 10 are deleted)
25 through a linker region and a new C-terminus created at
amino acid 96 of the original sequence.

Figure 3 shows a schematic of Method II, for
creating new proteins in which the original N-terminus
30 and C-terminus of the native protein are joined without
a linker and different N-terminus and C-terminus of the
protein are created. In the example shown the sequence
rearrangement results in a new gene encoding a protein
with a new N-terminus created at amino acid 97 of the
35 original protein, the original C-terminus (a.a. 174)
joined to the original N-terminus and a new C-terminus
created at amino acid 96 of the original sequence.

Figure 4 shows a schematic of Method III, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to amino acid 1 through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

Figure 5a and 5b shows the DNA sequence encoding the 209 amino acid mature form of flt3 ligand from Lyman et al. (*Oncogene* 11:1165-1172, 1995).

Figure 6 shows the DNA sequence encoding the 134 amino acid soluble form of flt3 ligand from Lyman et al. (*Oncogene* 11:1165-1172, 1995).

Figure 7 shows the bioactivity of the flt3 receptor agonists pMON32320 and pMON32321 compared to recombinant native flt3 (Genzyme) in the MUTZ-2 cell proliferation assay. MT = mock transfection.

Detailed Description of the Invention

Flt3 receptor agonists of the present invention may be useful in the treatment of diseases characterized by
5 decreased levels of hematopoietic cells.

A flt3 receptor agonist may be useful in the treatment or prevention of hematopoietic disorders. Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI,
10 alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, analgesics such as aminopyrine and dipyrone, anti-
15 convulsants such as phenytoin or carbamazepine, antithyroids such as propylthiouracil and methimazole and diuretics. flt3 receptor agonists may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients
20 treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections, burns and as a result of treatment for renal disease or renal failure, e.g., dialysis. The present peptide may
25 be useful in treating such hematopoietic deficiency.

Another aspect of the present invention provides plasmid DNA vectors for use in the method of expression of these novel flt3 receptor agonists. These vectors contain the novel DNA sequences described above which
30 code for the novel polypeptides of the invention. Appropriate vectors which can transform host cells capable of expressing the flt3 receptor agonists include expression vectors comprising nucleotide sequences coding for the flt3 receptor agonists joined to
35 transcriptional and translational regulatory sequences which are selected according to the host cells used. Vectors incorporating modified sequences as described

above are included in the present invention and are useful in the production of the modified flt3 receptor agonist polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and capable of directing the replication and expression thereof in selected host cells.

As another aspect of the present invention, there is provided a novel method for producing the novel family of human flt3 receptor agonists. The method of the present invention involves culturing suitable cells or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of the novel flt3 receptor agonist polypeptide. Suitable cells or cell lines may include various strains of bacteria such as *E. coli*, yeast, mammalian cells, or insect cells may be utilized as host cells in the method of the present invention.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the flt3 receptor agonists of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering

various factors which modify the action of drugs, e.g. the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.5 - 150 µg/kg of non-glycosylated flt3 receptor agonists protein per kilogram of body weight. Dosages would be adjusted relative to the activity of a given receptor agonist and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of flt3 receptor agonist would be adjusted higher or lower than the range of 0.5 - 150 micrograms per kilogram of body weight. These include co-administration with other CSF or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated flt3 receptor agonists; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate hematopoietins, CSFs and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (FLT3), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, human growth hormone, B-cell growth factor, B-cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF) also known as steel factor or c-kit ligand (herein collectively referred to as "factors"), or combinations thereof. In addition to the list above, IL-3 variants taught in WO 94/12639 and WO 94/12638 fusion protein taught in WO 95/21197, and WO 95/21254 G-CSF receptor agonists disclosed in WO 97/12977, c-mpl

receptor agonists disclosed in WO 97/12978, IL-3
receptor agonists disclosed in WO 97/12979 and multi-
functional receptor agonists taught in WO 97/12985 can
be co-administered with the polypeptides of the present
5 invention.

The flt3 receptor agonists of the present invention
may be useful in the mobilization of hematopoietic
progenitors and stem cells in peripheral blood.
10 Peripheral blood derived progenitors have been shown to
be effective in reconstituting patients in the setting
of autologous marrow transplantation. Hematopoietic
growth factors, including G-CSF and GM-CSF, have been
shown to enhance the number of circulating progenitors
15 and stem cells in the peripheral blood. This has
simplified the procedure for peripheral stem cell
collection and dramatically decreased the cost of the
procedure by decreasing the number of pheresis required.
The flt3 receptor agonist of the present invention may
20 be useful in mobilization of stem cells and further
enhance the efficacy of peripheral stem cell
transplantation.

The flt3 receptor agonists of the present invention
25 may also be useful in the ex vivo expansion of
hematopoietic progenitors. Colony stimulating factors
(CSFs), such as G-CSF, have been administered alone, co-
administered with other CSFs, or in combination with
bone marrow transplants subsequent to high dose
30 chemotherapy to treat the neutropenia and which is often
the result of such treatment. However the period of
severe neutropenia may not be totally eliminated. The
myeloid lineage, which is comprised of monocytes
(macrophages), granulocytes (including neutrophils) and
35 megakaryocytes, is critical in preventing infections and
bleeding which can be life-threatening. Neutropenia may
also be the result of disease, genetic disorders, drugs,

toxins, radiation and many therapeutic treatments such as conventional oncology therapy.

Bone marrow transplants have been used to treat this patient population. However, several problems are associated with the use of bone marrow to reconstitute a compromised hematopoietic system including: 1) the number of stem cells in bone marrow or other tissues, such as spleen or peripheral blood, is limited, 2) Graft Versus Host Disease, 3) graft rejection and 4) possible contamination with tumor cells. Stem cells and progenitor cells make up a very small percentage of the nucleated cells in the bone marrow, spleen and peripheral blood. It is clear that a dose response exists such that a greater number of multipotential hematopoietic progenitors will enhance hematopoietic recovery. Therefore, the in vitro expansion of stem cells should enhance hematopoietic recovery and patient survival. Bone marrow from an allogeneic donor has been used to provide bone marrow for transplant. However, Graft Versus Host Disease and graft rejection limit bone marrow transplantation even in recipients with HLA-matched sibling donors. An alternative to allogeneic bone marrow transplants is autologous bone marrow transplants. In autologous bone marrow transplants, some of the patient's own marrow is harvested prior to myeloablative therapy, e.g. high dose chemotherapy, and is transplanted back into the patient afterwards. Autologous transplants eliminate the risk of Graft Versus Host Disease and graft rejection. However, autologous bone marrow transplants still present problems in terms of the limited number of stem cells in the marrow and possible contamination with tumor cells. The limited number of multipotential hematopoietic progenitors may be overcome by ex-vivo expansion of the multipotential hematopoietic progenitors. In addition, stem cells can be specifically isolated based on the presence of specific surface

antigens such as CD34+ in order to decrease tumor cell contamination of the marrow graft.

- The following patents contain further details on
- 5 separating stem cells, CD34+ cells, culturing the cells with hematopoietic factors, the use of the cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy.
- 10 5,061,620 relates to compositions comprising human hematopoietic stem cells provided by separating the stem cells from dedicated cells.
- 15 5,199,942 describes a method for autologous hematopoietic cell transplantation comprising: (1) obtaining hematopoietic progenitor cells from a patient; (2) ex-vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand,
- 20 c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein and combinations thereof; (3) administering cellular preparation to a patient.
- 5,240,856 relates to a cell separator that includes an
- 25 apparatus for automatically controlling the cell separation process.
- WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a
- 30 mixture of cells.
- WO 91/18972 describes methods for in vitro culturing of bone marrow, by incubating suspension of bone marrow cells, using a hollow fiber bioreactor.
- 35 WO 92/18615 relates to a process for maintaining and expanding bone marrow cells, in a culture medium

containing specific mixtures of cytokines, for use in transplants.

WO 93/08268 describes a method for selectively expanding stem cells, comprising the steps of (a) separating CD34+ stem cells from other cells and (b) incubating the separated cells in a selective medium, such that the stem cells are selectively expanded.

WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood.

WO 93/18648 relates to a composition comprising human neutrophil precursor cells with a high content of myeloblasts and promyelocytes for treating genetic or acquired neutropenia.

WO 94/08039 describes a method of enrichment for human hematopoietic stem cells by selection for cells which express c-kit protein.

WO 94/11493 describes a stem cell population that are CD34+ and small in size, which are isolated using a counterflow elutriation method.

WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a nucleated heterogeneous cell population from a heterogeneous cell mixture.

WO 94/25848 describes a cell separation apparatus for collection and manipulation of target cells.

The long term culturing of highly enriched CD34+ precursors of hematopoietic progenitor cells from human bone marrow in cultures containing IL-1 α , IL-3, IL-6 or

GM-CSF is discussed in Brandt et al (*J. Clin. Invest.* 86:932-941, 1990).

One aspect of the present invention provides a method for selective ex-vivo expansion of stem cells. The term "stem cell" refers to the multipotential hematopoietic cells as well as early myeloid progenitor and precursors cells which can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the proliferation and differentiation of the cells. The present invention provides a method for selective ex-vivo expansion of stem cells, comprising the steps of; (a) separating stem cells from other cells, (b) culturing the separated stem cells with a selective medium which contains a flt3 receptor agonist and optionally a second colony stimulating factor, and (c) harvesting the cultured stems cells. Stem cells, as well as committed progenitor cells destined to become neutrophils, erythrocytes, platelets, etc., may be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as CD34, that are present on the surface of these cells and/or by morphological characteristics. The phenotype for a highly enriched human stem cell fraction is reported as CD34+, Thy-1+ and lin-, but it is to be understood that the present invention is not limited to the expansion of this stem cell population. The CD34+ enriched human stem cell fraction can be separated by a number of reported methods, including affinity columns or beads, magnetic beads or flow cytometry using antibodies directed to surface antigens such as the CD34+. Further, physical separation methods such as counterflow elutriation may be used to enrich hematopoietic progenitors. The CD34+ progenitors are heterogeneous, and may be divided into several sub-populations characterized by the presence or absence of co-expression of different lineage associated cell

surface associated molecules. The most immature progenitor cells do not express any known lineage associated markers, such as HLA-DR or CD38, but they may express CD90(thy-1). Other surface antigens such as

5 CD33, CD38, CD41, CD71, HLA-DR or c-kit can also be used to selectively isolate hematopoietic progenitors. The separated cells can be incubated in selected medium in a culture flask, sterile bag or in hollow fibers. Various colony stimulating factors may be utilized in order to

10 selectively expand cells. Representative factors that have been utilized for ex-vivo expansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF, IL-1, IL-6, IL-11, flt3 ligand or combinations thereof. The proliferation of the stem cells can be monitored by

15 enumerating the number of stem cells and other cells, by standard techniques (e.g. hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent to incubation.

Several methods for ex-vivo expansion of stem cells

20 have been reported utilizing a number of selection methods and expansion using various colony stimulating factors including c-kit ligand (Brandt et al., *Blood* **83**:1507-1514, 1994; McKenna et al., *Blood* **86**:3413-3420, 1995), IL-3 (Brandt et al., *Blood* **83**:1507-1514, 1994;

25 Sato et al., *Blood* **82**:3600-3609, 1993), G-CSF (Sato et al., *Blood* **82**:3600-3609, 1993), GM-CSF (Sato et al., *Blood* **82**:3600-3609, 1993), IL-1 (Muench et al., *Blood* **81**:3463-3473, 1993), IL-6 (Sato et al., *Blood* **82**:3600-3609, 1993), IL-11 (Lemoli et al., *Exp. Hem.* **21**:1668-

30 1672, 1993; Sato et al., *Blood* **82**:3600-3609, 1993), flt3 ligand (McKenna et al., *Blood* **86**:3413 3420, 1995) and/or combinations thereof (Brandt et al., *Blood* **83**:1507 1514, 1994; Haylock et al., *Blood* **80**:1405-1412, 1992, Koller et al., *Biotechnology* **11**:358-363, 1993; Lemoli et al.,

35 *Exp. Hem.* **21**:1668-1672, 1993), McKenna et al., *Blood* **86**:3413-3420, 1995; Muench et al., *Blood* **81**:3463-3473, 1993; Patchen et al., *Biotherapy* **7**:13-26, 1994; Sato et

al., *Blood* **82**:3600-3609, 1993; Smith et al., *Exp. Hem.* **21**:870-877, 1993; Steen et al., *Stem Cells* **12**:214-224, 1994; Tsujino et al., *Exp. Hem.* **21**:1379-1386, 1993). Among the individual colony stimulating factors, hIL-3
5 has been shown to be one of the most potent in expanding peripheral blood CD34+ cells (Sato et al., *Blood* **82**:3600-3609, 1993; Kobayashi et al., *Blood* **73**:1836-1841, 1989). However, no single factor has been shown to be as effective as the combination of multiple factors.
10 The present invention provides methods for ex vivo expansion that utilize novel flt3 receptor agonists.

Another aspect of the invention provides methods of sustaining and/or expanding hematopoietic precursor
15 cells which includes inoculating the cells into a culture vessel which contains a culture medium that has been conditioned by exposure to a stromal cell line such as HS-5 (WO 96/02662, Roecklein and Torok-Strob, *Blood* **85**:997-1105, 1995) that has been supplemented with a
20 flt3 receptor agonist of the present invention.

It is also envisioned that uses of flt3 receptor agonists of the present invention would include blood banking applications, where the flt3 receptor agonists
25 are given to a patient to increase the number of blood cells and blood products are removed from the patient, prior to some medical procedure, and the blood products are stored and transfused back into the patient after the medical procedure. Additionally, it is envisioned
30 that uses of flt3 receptor agonists would include giving the flt3 receptor agonists to a blood donor prior to blood donation to increase the number of blood cells, thereby allowing the donor to safely give more blood.

35 Another projected clinical use of growth factors has been in the in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the

- long life-span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the entire body, hematopoietic progenitor cells are good candidates for ex vivo gene transfection. In order to
- 5 have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell one needs to stimulate cell division and DNA replication. Hematopoietic stem cells cycle at a very low frequency which means that growth factors may be useful to promote
- 10 gene transduction and thereby enhance the clinical prospects for gene therapy. Potential applications of gene therapy (review Crystal, *Science* **270**:404-410, 1995) include; 1) the treatment of many congenital metabolic disorders and immunodeficiencies (Kay and Woo, *Trends*
- 15 *Genet.* **10**:253-257, 1994), 2) neurological disorders (Friedmann, *Trends Genet.* **10**:210-214, 1994), 3) cancer (Culver and Blaese, *Trends Genet.* **10**:174-178, 1994) and 4) infectious diseases (Gilboa and Smith, *Trends Genet.* **10**:139-144, 1994).
- 20 There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and non-viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include;
- 25 1) replication deficient recombinant retrovirus (Boris-Lawrie and Temin, *Curr. Opin. Genet. Dev.* **3**:102-109, 1993; Boris-Lawrie and Temin, *Annal. New York Acad. Sci.* **716**:59-71, 1994; Miller, *Current Top. Microbiol. Immunol.* **158**:1-24, 1992) and replication-deficient
- 30 recombinant adenovirus (Berkner, *BioTechniques* **6**:616-629, 1988; Berkner, *Current Top. Microbiol. Immunol.* **158**:39-66, 1992; Brody and Crystal, *Annal. New York Acad. Sci.* **716**:90-103, 1994). Non-viral based vectors include protein/DNA complexes (Cristiano et al., *PNAS*
- 35 *USA.* **90**:2122-2126, 1993; Curiel et al., *PNAS USA* **88**:8850-8854, 1991; Curiel, *Annal. New York Acad. Sci.* **716**:36-58, 1994), electroporation and liposome mediated

delivery such as cationic liposomes (Farhood et al., *Annal. New York Acad. Sci.* **716**:23-35, 1994).

The present invention provides an improvement to the existing methods of expanding hematopoietic cells, into which new genetic material has been introduced, in that it provides methods utilizing flt3 receptor agonists that may have improved biological activity and/or physical properties.

Another intended use of the flt-3 receptor agonists of the present invention is for the generation of larger numbers of dendritic cells, from precursors, to be used as adjuvants for immunization. Dendritic cells play a crucial role in the immune system. They are the professional antigen-presenting cells most efficient in the activation of resting T cells and are the major antigen-presenting cells for activation of naïve T cells *in vivo* and, thus, for initiation of primary immune responses. They efficiently internalize, process and present soluble tumor-specific antigens (Ag). Dendritic cells have the unique capacity to cluster naïve T cells and to respond to Ag encounter by rapid up-regulation of the expression of major histocompatibility complex (MHC) and co-stimulatory molecules, the production of cytokines and migration towards lymphatic organs. Since dendritic cells are of central importance for sensitizing the host against a neoantigen for CD4-dependent immune responses, they may also play a crucial role in the generation and regulation of tumor immunity.

Dendritic cells originate from a bone marrow CD34+ precursor common to granulocytes and macrophages, and the existence of a separate dendritic cell colony-forming unit (CFU-DC) that give rise to pure dendritic cell colonies has been established in humans. In addition, a post-CFU CD14+ intermediate has been described with the potential to differentiate along the dendritic cell or the macrophage pathway under distinct

cytokine conditions. This bipotential precursor is present in the bone marrow, cord blood and peripheral blood. Dendritic cells can be isolated by the cell specific marker, CD83, which is expressed on mature
5 dendritic cells, to delineate the maturation of cultured dendritic cells.

Dendritic cells based strategies provide a method for enhancing immune response against tumors and
10 infectious agents. AIDS is another disease for which dendritic cell based therapies can be used, since dendritic cells can play a major role in promoting HIV-1 replication. An immunotherapy requires the generation of dendritic cells from cancer patients, their *in vitro*
15 exposure to tumor Ag, derived from surgically removed tumor masses, and reinjection of these cells into the tumor patients. Relatively crude membrane preparations of tumor cells will suffice as sources of tumor antigen, avoiding the necessity for molecular identification of
20 the tumor antigen. The tumor antigen may also be synthetic peptides, carbohydrates, or nucleic acid sequences. In addition, concomitant administration of cytokines such as the flt-3 receptor agonists of the present invention may further facilitate the induction
25 of tumor immunity. It is foreseen that the immunotherapy can be in an *in vivo* setting, wherein the flt-3 receptor agonists of the present invention is administered to a patient, having a tumor, alone or with other hematopoietic growth factors to increase the number of
30 dendritic cells and endogenous tumor antigen is presented on the dendritic cells. It is also envisioned that *in vivo* immunotherapy can be with exogenous antigen. It is also envisioned that the immunotherapy treatment may include the mobilization of dendritic cell
35 precursors or mature dendritic, by administering the flt-3 receptor agonists of the present invention alone or with other hematopoietic growth factors to the patient, removing the dendritic cell precursors or

mature dendritic cells from the patient, exposing the dendritic cells to antigen and returning the dendritic cells to the patient. Furthermore, the dendritic cells that have been removed can be cultured *ex vivo* with the
5 flt-3 receptor agonists of the present invention alone or with other hematopoietic growth factors to increase the number of dendritic cells prior to exposure to antigen. Dendritic cells based strategies also provide a method for reducing the immune response in auto-immune
10 diseases.

Studies on dendritic cells have been greatly hampered by difficulties in preparing the cells in sufficient numbers and in a reasonably pure form. In an
15 *ex-vivo* cell expansion setting, granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor- α (TNF- α) cooperate in the *ex vivo* generation of dendritic cells from hematopoietic progenitors (CD34+ cells) retrieved from bone marrow, cord blood, or
20 peripheral blood and flk-2/flt-3 ligand and c-kit ligand (stem cell factor [SCF]) synergize to enhance the GM-CSF plus TNF- α induced generation of dendritic cells (Siena, S. *et al. Experimental Hematology* 23:1463-1471, 1995). Also provide is a method of *ex vivo* expansion of
25 dendritic cell precursors or mature dendritic cells using the flt-3 receptor agonists of the present invention to provide sufficient quantities of dendritic cells for immunotherapy.

30 Determination of the Linker

The length of the amino acid sequence of the linker can be selected empirically or with guidance from structural information, or by using a combination of the
35 two approaches.

When no structural information is available, a small series of linkers can be prepared for testing

using a design whose length is varied in order to span a range from 0 to 50 Å and whose sequence is chosen in order to be consistent with surface exposure (hydrophilicity, Hopp & Woods, *Mol. Immunol.* **20**: 483-489, 1983; Kyte & Doolittle, *J. Mol. Biol.* **157**:105-132, 1982; solvent exposed surface area, Lee & Richards, *J. Mol. Biol.* **55**:379-400, 1971) and the ability to adopt the necessary conformation without deranging the configuration of the flt3 receptor agonist

10 (conformationally flexible; Karplus & Schulz, *Naturwissenschaften* **72**:212-213, (1985). Assuming an average of translation of 2.0 to 3.8 Å per residue, this would mean the length to test would be between 0 to 30 residues, with 0 to 15 residues being the preferred

15 range. Exemplary of such an empirical series would be to construct linkers using a cassette sequence such as Gly-Gly-Gly-Ser repeated n times, where n is 1, 2, 3 or 4. Those skilled in the art will recognize that there are many such sequences that vary in length or

20 composition that can serve as linkers with the primary consideration being that they be neither excessively long nor short (cf., Sandhu, *Critical Rev. Biotech.* **12**: 437-462, 1992); if they are too long, entropy effects will likely destabilize the three-dimensional fold, and

25 may also make folding kinetically impractical, and if they are too short, they will likely destabilize the molecule because of torsional or steric strain.

Those skilled in the analysis of protein structural

30 information will recognize that using the distance between the chain ends, defined as the distance between the c-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that must be tested in an empirical

35 selection of linkers. They will also recognize that it is sometimes the case that the positions of the ends of the polypeptide chain are ill-defined in structural

models derived from x-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when true, this situation will therefore need to be taken into account in order to properly estimate the length of the linker required. From those residues whose positions are well defined are selected two residues that are close in sequence to the chain ends, and the distance between their c-alpha carbons is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8Å per residue) are then selected. These linkers may be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues may be chosen to be flexible and hydrophilic as described above; or optionally the original sequence may be substituted for using a series of linkers, one example being the Gly-Gly-Gly-Ser cassette approach mentioned above; or optionally a combination of the original sequence and new sequence having the appropriate total length may be used.

Determination of the Amino and Carboxyl Termini of flt3 Receptor Agonists

Sequences of flt3 receptor agonists capable of folding to biologically active states can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while using the linker sequence as described above. Amino and carboxyl termini are selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases the selection of the new termini will be such that the

original position of the carboxyl terminus immediately preceded that of the amino terminus. However, those skilled in the art will recognize that selections of termini anywhere within the region may function, and
5 that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.

It is a central tenet of molecular biology that the primary amino acid sequence of a protein dictates
10 folding to the three-dimensional structure necessary for expression of its biological function. Methods are known to those skilled in the art to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear
15 magnetic resonance spectroscopy of protein solutions. Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta
20 sheets, chain reversals and turns, and loops; Kabsch & Sander, *Biopolymers* **22**: 2577-2637, 1983; the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, *Ann. Rev. Biochem.* **53**:537-572; 1984) and the
25 static and dynamic distribution of conformations along the polypeptide chain (Alber & Mathews, *Methods Enzymol.* **154**: 511-533, 1987). In some cases additional information is known about solvent exposure of residues; one example is a site of post-translational attachment
30 of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or is not feasible to obtain, methods are also available to analyze the primary amino acid sequence in order to make predictions of protein
35 tertiary and secondary structure, solvent accessibility and the occurrence of turns and loops. Biochemical methods are also sometimes applicable for empirically

determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure

5 (Gentile & Salvatore, *Eur. J. Biochem.* **218**:603-621, 1993). Thus using either the experimentally derived structural information or predictive methods (e.g., Srinivisan & Rose *Proteins: Struct., Funct. & Genetics*, **22**: 81-99, 1995) the parental amino acid sequence is

10 inspected to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel

15 and anti-parallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so-called hydrophobic core of the protein and should also

20 be avoided for selection of amino and carboxyl termini. In contrast, those regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, are the preferred sites for location of the

25 extremes of the polypeptide chain. Continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as a breakpoint region.

TABLE 1
OLIGONUCLEOTIDES

5	NCOFLT	CTGACCATGGCNACCCAGGACTGCTCCTTCCAA SEQ ID NO:57;
	HIND160	ACTGAAGCTTAGGGCTGACACTGCAGCTCCAG SEQ ID NO:58;
	HIND165	ACTGAAGCTTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO:59;
10	FL23For	GACTGCCATGGCNACYCAGGAYTGTYCTTYCAACACAGCCCCATC SEQ ID NO:60;
	FH3AFor	GACTGCCATGGCNACYCAGGAYTGTYCTTYCAACACAGCCCCATC SEQ ID NO:61;
15	SCF.REV	TGTCCAAACTCATCAATGTATC SEQ ID NO:62;
	39FOR	CATGGCCATGGCGACGAGGAGCTCTGCGGGGCTCT SEQ ID NO:63;
	39REV	GCTAGAAGCTTACTGCAGGTTGGAGGCCACGGTGAC SEQ ID NO:64;
20	65FOR	CATGGCCATGGCCTCCAAGATGCAAGGCTTGCTGGAGC SEQ ID NO:65;
	65REV	GCTAGAAGCTTACCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO:66;
	89FOR	CATGGCCATGGCCCCCCCCAGCTGTCTTCGCTTCGT SEQ ID NO:67;
25	89REV	GCTAGAAGCTTAGGGCTGAAAGGCACATTTGGTGACA SEQ ID NO:68;
	L5A	CCCTGTCTGGCGGCAACGGCAGGACTGCTCCTTCCAAC SEQ ID NO:69;
	L10A	GCGGTAACGGCAGTGGAGGTAATGGCAGGACTGCTCCTTCCAAC SEQ ID NO:70;
35	L15A	ACGGCAGTGGTGGCAATGGGAGCGCGGAAATGGAACCCAGGACTGCTCCT TCCAAC SEQ ID NO:71;
	L5B	GTGCCGTTGCCGCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO:72;
40	L10B	ATTACCTCCACTGCCGTTACCGCTGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO:73;
	L15B	GCTCCCATGCCCACCACTGCCGTTACCTCCAGACAGGGTTGAGGA GTCGGGCTG SEQ ID NO:74;
45	L15C	GATGAGGATCCGGTGGCAATGGGAGCGCGGAAATGGAACCCAGG ACTGCTCCTTCCACC SEQ ID NO:75;
	L15D	GATGACGGATCCGTTACCTCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO:76;
50	L15E	GATGACGGATCCGGAGGTAATGGCAGGACTGCTCCTTCCAAC SEQ ID NO:77;

	339FOR2	GACTGCCATGGCCGACGAGGAGCTCTGCG SEQ ID NO:78;
	339REV2	GACTCAAGCTTACTGCAGGTTGGAGGCC SEQ ID NO:79;
5	339-10FOR3	GACTCGGGATCCGGAGGTTCTGGCACCCAGGACTGCTCC SEQ ID NO:80;
	339-15FOR2	GACTGGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACC SEQ ID NO:81;
	339REV3	GACTTGGGATCCACTACCTCCAGACAGGGTTGAGGAGTC SEQ ID NO:82;
10	FLN3	ACTGACGGATCCACCGCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO:83;
	FLN7	ACTGACGGATCCACCTCCTGACCCACCGCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO:84;
15	FLN11	ACTGACGGATCCACCTCCTGACCCACCTCCTGACCCACCGCCAG GGTTGAGGAGTCGGGCTG SEQ ID NO:85;
	C-term	ACGTAAAGCTTACAGGTTGAGGAGTCG SEQ ID NO:86;
20	FLC3	GTCAGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAAC SEQ ID NO:87;
	FLC4	GTCAGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO:88;
25	FLC10	GTCAGTGGATCCGGAGGTGGCTCAGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAAC SEQ ID NO:89;
	Flt36	GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGTGCGGGGCCTCTGG CGGCTG SEQ ID NO:90;
30	Flt37	GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGTGYGGGGCCTCTGGCG GCTGGTC SEQ ID NO:91;
	Flt38	GTTGCCATGGCNTGCARGAYGARGARCTGTGYGGYGGCCTCTGGCGGCTG GTCCTG SEQ ID NO:92;
	Flt39	GTTGCCATGGCNCARGAYGARGARCTGTGYGGYGGYCTCTGGCGGCTGGTC CTGGCA SEQ ID NO:93;
40	Flt40	GTTGCCATGGCNGAYGARGARCTGTGYGGYGGYCTCTGGCGGCTGGTCCTG GCACAG SEQ ID NO:94;
	Flt41	GTTGCCATGGCNGARGARCTGTGYGGYGGYCTCTGGCGGCTGGTCCTGGCA CAGCGC SEQ ID NO:95;
45	Flt42	GTTGCCATGGCNGARCTGTGYGGYGGYCTGTGGCGYCTGCTCCTGGCACAG CGCTGG SEQ ID NO:96;
	Flt43	GTTGCCATGGCNTGTGYGGYGGYCTGTGGCGYCTGCTCCTGGCACAGCGC TGGATG SEQ ID NO:97;
50	36REV	TATGCAAGCTTAGGCCACGGTGACTGGGTA SEQ ID NO:98;
55	37REV	TATGCAAGCTTAGGAGGCCACGGTGACTGG SEQ ID NO:99;

WO 98/18923

PCT/US97/18700

	38REV	TATGCAAGCTTAGTTGGAGGCCACGGTGAC SEQ ID NO:100;
	39REV	TATGCAAGCTTACAGGTTGGAGGCCACGGT SEQ ID NO:101;
5	40REV	TATGCAAGCTTACTGCAGGTTGGAGGCCAC SEQ ID NO:102;
	41REV	TATGCAAGCTTAGTCCTGCAGGTTGGAGGC SEQ ID NO:103;
10	42REV	TATGCAAGCTTACTCGTCCTGCAGGTTGGA SEQ ID NO:104;
	43REV	TATGCAAGCTTACTCCTCGTCCTGCAGGTT SEQ ID NO:105;

TABLE 2
DNA sequences

5	pMON30237.seq	GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC CAAGATGCAAGGCTTGTCTGGAGCGCTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCGCTCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT AGCCC SEQ ID NO:106;
15	pMON30238.seq	GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC CAAGATGCAAGGCTTGTCTGGAGCGCTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCGCTCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT AGCCCCACTCTCAACCTG SEQ ID NO:107;
30	pMON30239.seq	GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC CAAGATGCAAGGCTTGTCTGGAGCGCTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTAGCC CGACTCCTCAACCTG SEQ ID NO:108;
40	pMON32329.seq	GGAACCTCAGGATTGTTCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG CTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC CAAGATGCAAGGCTTGTCTGGAGCGCTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCGCTCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT AGCCC SEQ ID NO:109;
55	pMON32330.seq	

GGTACCCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC
TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA
CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG
5 CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC
CAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGTCA
CCAAATGTGCCTTTAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC
AACATCTCCCGCCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA
GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTG
10 AGCCCCGACTCCTCAACCTG SEQ ID NO:110;

pMON32341.seq

15 GCCACTCAGGACTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC
TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA
CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG
CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC
CAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGTCA
20 CCAAATGTGCCTTTAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC
AACATCTCCCGCCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA
GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTG
AGCCCC SEQ ID NO:111;

25 pMON32342.seq

GCCACTCAGGACTGCTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC
TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA
CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG
30 CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTC
CAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGTCA
CCAAATGTGCCTTTAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC
AACATCTCCCGCCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA
GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTG
35 AGCCCCGACTCCTCAACCTG SEQ ID NO:112;

pMON32320.seq

40 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
45 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTGAGCCGACTCCTCAACC
CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGAAATGGAAC
CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAACGTC
50 GCCTCCAACCTGCAG SEQ ID NO:113;

pMON32321.seq

55 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACAGCCGACTCCTCAACC
CTGTCAAGCGGTAAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT
CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT
5 CTGACTACCTGCTTCAAGATTACCCAGTACCGTGGCCTCCAACCTGCAG
SEQ ID NO:114;

pMON32322.seq

10 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC'TGGTCTTGCCACAGCG
CTGGATGGAGCGGCTCAAGACTGTGCGTGGGTCCAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCTTTCAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
15 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACAGCCGACTCCTCAACC
CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT
CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC
AAGATTACCCAGTACCGTGGCCTCCAACCTGCAG SEQ ID NO:115;

20

pMON32323.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAATGTGCTTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
25 AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTGAGCCGACTCCTCAACCTGTCTGGAGGTAAACGGATCCGGTGGCA
ATGGGAGCGCGGAAATGGAAACCCAGGACTGCTCCTTCCAACACAGCCCC
ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT
30 TCAAGATTACCCAGTACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT
GCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCGCTGGATGGAGCGGCTC
AAGACTGTGCTGGG SEQ ID NO:116;

35

pMON32324.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAATGTGCTTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
40 CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTGAGCCCGACTCCTCAACCTGTCTGGAGGTAAACGGATCCGGAGGTA
ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC
GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT
CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC
45 GGCTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGG
SEQ ID NO:117;

pMON32325.seq

50 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAATGTGCTTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTGAGCCCGACTCCTCAACCTGTCTGGCGGCAACGGCACGAGGACT
55 GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT
GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTACCGTGGCCTCAA

CCTGCAGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCAC
AGCGCTGGATGGAGCGGCTCAAGACTGTCTGGTGGG SEQ ID NO:118;

5 pMON32326.seq

10 GCGGGGGGAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCGGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCGGACTCCTCAACC
CTGTCTGGAGGTAAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC
CCAGGACTGTCTCTTCCAACACAGCCCCATCTCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG
GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT
CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCTGGTGGTCCAAGA
15 TGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGTACACAAA
TGTGCCTTTTCAAGCC SEQ ID NO:119;

pMON32327.seq

20 GCGGGGGGAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCGGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCGGACTCCTCAACC
CTGTCTGGCGGTAACGGCAGTGGAGGTAAATGGCACCCAGGACTGTCTT
25 CCAACACAGCCCCATCTCTCCGACTTCGCTGTCTCAAAATCCGTGAGCTGT
CTGACTACCTGTCTCAAGATTACCCAGTCACCGTGGCTCCAACCTGCAG
GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTGGGCACAGCGCTG
GATGGAGCGGCTCAAGACTGTCTGGTGGTCCAAGATGCAAGGCTTGCTGG
AGCGCGTGAACACGGAGATACACTTTGTACACAAATGTGCCTTTCAAGCC
30 SEQ ID NO:120;

pMON32328.seq

35 GCGGGGGGAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCGGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCGGACTCCTCAACC
CTGTCTGGCGGCAACGGCACGACGAGGACTGTCTTCCAACACAGCCCCAT
CTCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC
AAGATTACCCAGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGC
40 GGGGGCCTCTGGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAA
GACTGTCTGGTCCAAGATGCAAGGCTTGCTGGAGCGGCTGAACACGG
AGATACACTTTGTACACAAATGTGCCTTTCAAGCC SEQ ID NO:121;

45 pMON32348.seq

50 GCGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCTGGTGGTCCAAGATGCAAGGCTTGC
TGGAGCGGTGAACACGGAGATACACTTTGTACACAAATGTGCCTTTCAAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCGGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCGGACTCCTCAACC
CTGTCTGGAGGTAGTGGATCCGGAGGTTCTGGCAACCCAGGACTGTCTCT
TCCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAAATCCGTGAGCTG
55 TCTGACTACCTGTCTCAAGATTACCCAGTCACCGTGGCTCCAACCTGCA
G SEQ ID NO:122;

pMON32350.seq

5 GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAATGTGCCTTTCAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
10 GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGTGCCTGGAGCTGCAGTGTACGCCGACTCCTCAACC
CTGTCTGGAGGTAGTGGATCCGGTGGCAGTGGGAGCGCGGATCTGGAAC
CCAGGACTGCTCCTTCCAACACAGCCCCATCTCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG
15 GCCTCCAACCTGCAG SEQ ID NO:123;

FLT3N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC
20 TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC
AGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCT
GGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT
GGGTCCAAGATGCAAGGCTTGTGGAGCGCGTGAACACGGAGATACACTT
TGTACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
25 AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGCTGCA
GTGTACGCCGACTCCTCAACCTGGGCGGTGGATCC SEQ ID NO:124;

FLT3C.seq

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC
CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT
35 ACCCAGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC
CTCTGGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT
CGCTGGGTCCAAGATGCAAGGCTTGTGGAGCGCGTGAACACGGAGATAC
ACTTTGTACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTC
GTCCAGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGT
40 GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGC
TGCACTGTACGCCGACTCCTCAACCTGTAAGCTT SEQ ID NO:125;

FLT7N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC
45 TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC
AGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCT
GGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT
GGGTCCAAGATGCAAGGCTTGTGGAGCGCGTGAACACGGAGATACACTT
50 TGTACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGCTGCA
GTGTACGCCGACTCCTCAACCTGGGCGGTGGGTGAGGAGGTGATCC
55 SEQ ID NO:126;

FLT4C.seq

GGATCCGGAGGTGGCACCAGGACTGCTCCTTCCAACACAGCCCCATCTC
CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG
ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG
5 GGCCCTCTGGCGGCTGGTCTTGCACAGCGCTGGATGGAGCGCTCAAGAC
TGTGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGA
TACACTTTGTACCAAAATGTGCCTTTACGCCCCCCCCAGCTGTCTTCGC
TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT
GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG
10 AGCTGCAGTGTACGCCCCGACTCCTCAACCTGTAAAGCTT SEQ ID NO:127;

FLT11N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCTCCGAC
TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC
AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCT
GGCGGCTGGTCTTGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCT
GGGTCCAAGATGCAAGGCTTGCTGGAGCGGCTGAACACGGAGATACACTT
20 TGTACCAAAATGTGCCTTTACGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTACGCCCCGACTCCTCAACCTGGGCGGTGGGTACGAGGTGGGTACG
GAGGTGGATCC SEQ ID NO:128;

FLT10C.seq

GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT
CCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT
30 CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCTCCAACCTGCAG
GACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGTCTTGCACAGCGCTG
GATGGAGCGGCTCAAGACTGTCTGCTGGGTCCAAGATGCAAGGCTTGCTGG
AGCGCGTGAACACGGAGATACACTTTGTACCAAAATGTGCCTTTACGCCC
CCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCTGCA
35 GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA
ACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCCGACTCCTCAACCTGT
TAAGCTT SEQ ID NO:129;

pMON32365.seq

GCCGACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGTCCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCTGAACACGGAGATACACTTTGTACCAAAATGTGCCTTTAG
45 CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCGACTCCTCAACC
CTGGGCGGTGGATCCGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC
CATCTCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC
50 TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:130;

pMON32366.seq

GCCGACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGTCCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCAGCTGCTTCGCTTCGTCCAGACCAACATCTCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTAGCCCGACTCCTCAACC
5 CTGGGCGGTGGATCCGAGGTGGCAGCCAGACTGCTCCTTCCAACACAG
CCCCATCTCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACC
TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:131;

10 pMON32367.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
15 TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCAGCTGCTTCGCTTCGTCCAGACCAACATCTCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTAGCCCGACTCCTCAACC
CTGGGCGGTGGTCAAGGAGGTGGATCCGAGGTACCCAGGACTGCTCCTT
CCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAATCCGTGAGCTGT
20 CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG
SEQ ID NO:132;

pMON32368.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCG
25 CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCAGCTGCTTCGCTTCGTCCAGACCAACATCTCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
30 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTAGCCCGACTCCTCAACC
CTGGGCGGTGGATCCGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA
CTGCTCCTTCCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAATCC
GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC
AACCTGCAG SEQ ID NO:133;

35

pMON32369.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCG
40 CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCAGCTGCTTCGCTTCGTCCAGACCAACATCTCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTAGCCCGACTCCTCAACC
45 CTGGGCGGTGGTCAAGGAGGTGGTCAAGGAGGTGGATCCGAGGTGGCAC
CCAGGACTGCTCCTTCCAACACAGCCCCATCTCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG
GCCTCCAACCTGCAG SEQ ID NO:134;

50 pMON32370.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
55 CCCCCCCCAGCTGCTTCGCTTCGTCCAGACCAACATCTCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCCGACTCCTCAACC
CTGGGCGGTGGGTTCAGGAGGTGGGTTCAGGAGGTGGATCCGGAGGTGGCTC
AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT
CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA
5 GATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:135;

pMON35712.seq

10 GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGGGGG
GCCTCTGGCGGTGGTCTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTTCGC
TGGGTCCAAGATGCAAGGCTTGGTGGAGCGCGTGAACACGGAGATACACTTTGTC
ACCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCAGACCAACA
TCTCCCGCTCTTCGAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT
CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCCGACTCCTCA
15 ACCCTGGGCGGTGGGTTCAGGAGGTGGGTTCAGGAGGTGGATCCGGAGGTGGCACC
AGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG
TGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO:136;

pMON35713.seq

20 GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGGGGGGCCTCTGGCGGTGGTCC
TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTTCGCTGGGTCCAAGATGCAAGG
CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG
CCCCCCCCAGCTGTCTTCGCTTCGTCAGACCAACATCTCCCGCTCTTCGAGG
25 AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC
CCGGTGCCTGGAGCTGCAGTGTACGCCCCGACTCCTCAACCTGGGCGGTGGGTCA
GGAGGTGGGTTCAGGAGGTGGATCCGGAGGTGGCACCAGGACTGCTCCTTCCAAC
ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT
GCTTCAAGATTACCCAGTCACCGTG SEQ ID NO:137;

pMON35714.seq

30 GCCGTGCTGGGTCCAAGATGCAAGGCTTGGTGGAGCGCGTGAACACGGAGATAC
ACTTTGTACCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCA
35 GACCAACATCTCCCGCTCTTCGAGGAGACTCCGAGCAGCTGGTGGCGCTGAAG
CCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCCG
ACTCCTCAACCTGGGCGGTGGGTTCAGGAGGTGGGTTCAGGAGGTGGATCCGGAGG
TGGCACCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC
AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT
40 CCAACCTGCAGGACGAGGAGCTCTGGGGGGCCTCTGGCGGTGCTCCTGGCACA
GCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO:138;

pMON35715.seq

45 GCCTCCAAGATGCAAGGCTTGGTGGAGCGCGTGAACACGGAGATACACTTTGTCA
CCAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCAGACCAACAT
CTCCCGCTCTTCGAGGAGACTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC
ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTACGCCCCGACTCCTCAA
CCCTGGGCGGTGGGTTCAGGAGGTGGGTTCAGGAGGTGGATCCGGAGGTGGCACC
50 GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT
GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC
AGGACGAGGAGCTCTGGGGGGCCTCTGGCGGTGGTCTTGGCACAGCGCTGGAT
GGAGCGGCTCAAGACTGTCTGCTGGG SEQ ID NO:139;

55 pMON35716.seq

5 GCGGGGCTCGTGGCGCTGCGTCCAGACCAACATCTCCCGCTCCTGCAGG
AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC
CCGGTGCCTGGAGCTGCAGTGTGAGCCGACTCCTCAACCCCTGGCGGTGGGTCA
GGAGGTGGGTGAGGAGGTGGATCCGGAGGTGGCACCAGGACTGCTCCTTCCAAC
ACAGCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT
GCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTGTC
GGGGGCTCTGGCGGCTGGTCCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTG
TCGCTGGGTCCAAGATGCAAGGCTTGTGGAGCGGTGAACACGGAGATACACTT
TGTCACCAAATGTGCTTTCAGCCC SEQ ID NO:140;

10

pMON 35717.seq

15 GCGCGCTTCGTCAGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGC
TGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGCT
GCAGTGTGAGCCGACTCCTCAACCCCTGGCGGTGGGTGAGGAGGTGGGTGAGGA
GGTGGATCCGGAGGTGGCACCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT
CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC
AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCTCTGGCGG
CTGGTCCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGA
20 TGAAGGCTTGTGGAGCGGTGAACACGGAGATACACTTGTACCAAATGTGC
CTTTCAGCCCCCCCCAGCTGTCTT SEQ ID NO:142;

pMON 35718.seq

25 GCCACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA
AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTGAGCC
CGACTCCTCAACCCCTGGCGGTGGGTGAGGAGGTGGGTGAGGAGGTGGATCCGGA
GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCGGACTTCGCTG
TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC
30 CTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCTCTGGCGGCTGGTCCCTGGCA
CAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCTGAACACGGAGATACACTTGTACCAAATGTGCTTTCAGCCCCC
CCCCAGCTGTCTCGCTTCGTCCAG SEQ ID NO:143;

TABLE 3
PROTEIN SEQUENCES

5	pMON30237.pep
	AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
	ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
	AspGluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
10	LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
	HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr
	AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
	ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO:1;
15	pMON30238.pep
	AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
	ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
20	AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
	LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
	HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr
	AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
25	ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu
	SEQ ID NO:2;
	pMON30239.pep
	AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
30	ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
	AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
	LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
	HisPheValThrLysCysAlaPheGlnGluThrSerGluGlnLeuValAlaLeuLysPro
	TrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer
35	ThrLeu SEQ ID NO:3;
	pMON32329.pep
40	GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
	ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
	AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
	LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
	HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr
45	AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
	ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO:4;
	pMON32330.pep
50	GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
	ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
	AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
	LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
55	HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr

AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu
SEQ ID NO:5;

5 pMON32341.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
10 AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr
AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO:6;

15 pMON32342.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
20 AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr
AsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIle
ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu
25 SEQ ID NO:7;

pMON32320.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
30 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys
35 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:8;

pMON32321.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
40 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer
ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp
45 TyrProValThrValAlaSerAsnLeuGln SEQ ID NO:9;

50 pMON32322.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
55 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp

IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
AlaSerAsnLeuGln SEQ ID NO:10;

5

pMON32323.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro
IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr
ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu
ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:11;

10

15

pMON32324.pep

20

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe
AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla
SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg
TrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:12;

25

30

pMON32325.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg
GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp
GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu
LysThrValAlaGly SEQ ID NO:13;

35

40

pMON32326.pep

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn
GlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln
ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg
ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:14;

45

50

55 pMON32327.pep

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
 SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
 GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn
 GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
 5 ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
 AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
 LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
 HisPheValThrLysCysAlaPheGlnPro SEQ ID NO:15;

10

pMON32328.pep

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
 SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
 15 GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCys
 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
 TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys
 GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla
 GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
 20 CysAlaPheGlnPro SEQ ID NO:16;

pMON32348.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
 ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
 30 LeuSerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGlyThrGlnAspCys
 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
 TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:17;

35

pMON32350.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
 40 ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
 LeuSerGlyGlySerGlySerGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer
 ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp
 TyrProValThrValAlaSerAsnLeuGln SEQ ID NO:18;

45

FLT3N.pep

MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys
 IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu
 GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
 ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
 50 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
 LeuGlyGlyGlySer SEQ ID NO:19;

55

FLT3C.pep

5 GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla
ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer
AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp
MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn
10 ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe
ValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys
ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer
SerThrLeu SEQ ID NO:20;

15 FLT7N.pep

MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys
IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu
GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
20 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
25 LeuGlyGlyGlySerGlyGlyGlySer SEQ ID NO:21;

FLT4C.pep

GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe
30 AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla
SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg
TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal
AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg
PheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu
35 LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp
SerSerThrLeu SEQ ID NO:22;

FLT11N.pep

40 MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys
IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu
GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
45 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO:23;

50

FLT10C.pep

GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer
ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp
55 TyrProValThrValAlaSerAsnLeuGlnAspGluLeuCysGlyGlyLeuTrpArg
LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln

GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro
ProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSer
GluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu
LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:24;

5

pMON32365.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer
15 AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr
ValAlaSerAsnLeuGln SEQ ID NO:25;

20

pMON32366.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
25 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer
SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal
ThrValAlaSerAsnLeuGln SEQ ID NO:26;

30

pMON32367.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
35 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSer
ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp
40 TyrProValThrValAlaSerAsnLeuGln SEQ ID NO:27;

pMON32368.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
50 LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe
GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu
LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:28;

55

pMON32369.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
 ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
 5 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
 LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys
 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
 TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:29;

10 pMON32370.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu
 ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu
 15 IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
 ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
 IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
 LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly
 20 IleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu
 Gln SEQ ID NO:30;

pMON35712.pep

AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu
 TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys
 25 MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe
 GlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGlu
 ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys
 30 LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer
 GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer
 AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO:31;

pMON35713.pep

AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla
 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu
 ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys
 35 LeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal
 AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln
 40 ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
 GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
 ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO:32;

45 pMON35714.pep

AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe
 ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIle
 SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArg
 50 GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly
 GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln
 HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu
 GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu
 55 TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO:33;

pMON35715.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
5 SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly
GlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro
IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr
ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu
ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:34;

10 pMON35716.pep

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
15 GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly
GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln
ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg
20 ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:35;

pMON35717.pep

AlaArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal
25 AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln
ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
30 LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
HisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO:36;

pMON35718.pep

AlaThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro
35 TrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer
ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp
CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer
AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu
40 CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal
AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr
LysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO:37;

45

Materials and Methods

Recombinant DNA methods

Unless noted otherwise, all specialty chemicals
5 were obtained from Sigma Co., (St. Louis, MO).
Restriction endonucleases and T4 DNA ligase were
obtained from New England Biolabs (Beverly, MA) or
Boehringer Mannheim (Indianapolis, IN).

10 Transformation of *E. coli* strains

E. coli strains, such as DH5 α [™] (Life Technologies,
Gaithersburg, MD) and TG1 (Amersham Corp., Arlington
Heights, IL) are used for transformation of ligation
15 reactions and are the source of plasmid DNA for
transfecting mammalian cells. *E. coli* strains, such as
MON105 and JM101, can be used for expressing the flt3
receptor agonist of the present invention in the
cytoplasm or periplasmic space.

20 MON105 ATCC#55204: F⁻, lamda⁻, IN(rrnD, rrE)1, rpoD⁺,
rpoH358

DH5 α [™]: F⁻, phi80dlacZdeltaM15, delta(lacZYA-argF)U169,
25 deoR, recA1, endA1, hsdR17(rk⁻,mk⁺), phoA, supE44lamda⁻,
thi-1, gyrA96, relA1

TG1: delta(lac-pro), supE, thi-1, hsdD5/F'(traD36,
proA+B⁺, lacIq, lacZdeltaM15)

30 DH5 α [™] Subcloning efficiency cells are purchased as
competent cells and are ready for transformation using
the manufacturer's protocol, while both *E. coli* strains
TG1 and MON105 are rendered competent to take up DNA
35 using a CaCl₂ method. Typically, 20 to 50 mL of cells
are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto-
yeast extract, 150 mM NaCl) to a density of

approximately 1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, NY). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl_2 solution (50 mM CaCl_2 , 10 mM Tris-Cl, pH 7.4) and are held at 4°C for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl_2 solution. Ligated DNA is added to 0.2mL of these cells, and the samples are held at 4°C for 1 hour. The samples are shifted to 42°C for two minutes and 1mL of LB is added prior to shaking the samples at 37°C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37°C. Single colonies are picked, grown in LB supplemented with appropriate antibiotic for 6-16 hours at 37°C with shaking. Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37°C while shaking. Before harvesting the cultures, 1 ul of cells are analyzed by PCR for the presence of a *flt3* receptor agonist gene. The PCR is carried out using a combination of primers that anneal to the *flt3* receptor agonist gene and/or vector. After the PCR is complete, loading dye is added to the sample followed by electrophoresis as described earlier. A gene has been ligated to the vector when a PCR product of the expected size is observed.

Methods for creation of genes with new N-terminus/C-terminus

Method I. Creation of genes with new N-terminus/C-terminus which contain a linker region.

Genes with new N-terminus/C-terminus which contain
5 a linker region separating the original C-terminus and
N-terminus can be made essentially following the method
described in L. S. Mullins, et al *J. Am. Chem. Soc.* **116**,
5529-5533 (1994). Multiple steps of polymerase chain
10 reaction (PCR) amplifications are used to rearrange the
DNA sequence encoding the primary amino acid sequence of
the protein. The steps are illustrated in Figure 2.

In the first step, the primer set ("new start" and
"linker start") is used to create and amplify, from the
15 original gene sequence, the DNA fragment ("Fragment
Start") that contains the sequence encoding the new N-
terminal portion of the new protein followed by the
linker that connects the C-terminal and N-terminal ends
of the original protein. In the second step, the primer
20 set ("new stop" and "linker stop") is used to create and
amplify, from the original gene sequence, the DNA
fragment ("Fragment Stop") that encodes the same linker
as used above, followed by the new C-terminal portion of
the new protein. The "new start" and "new stop" primers
25 are designed to include the appropriate restriction
enzyme recognition sites which allow cloning of the new
gene into expression plasmids. Typical PCR conditions
are one cycle 95°C melting for two minutes; 25 cycles
94°C denaturation for one minute, 50°C annealing for one
30 minute and 72°C extension for one minute; plus one cycle
72°C extension for seven minutes. A Perkin Elmer
GeneAmp PCR Core Reagents kit is used. A 100 ul
reaction contains 100 pmole of each primer and one ug of
template DNA; and 1x PCR buffer, 200 uM dGTP, 200 uM
35 dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA
polymerase and 2 mM MgCl₂. PCR reactions are performed

in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT).

- "Fragment Start" and "Fragment Stop", which have
- 5 complementary sequence in the linker region and the coding sequence for the two amino acids on both sides of the linker, are joined together in a third PCR step to make the full-length gene encoding the new protein. The DNA fragments "Fragment Start" and "Fragment Stop" are
- 10 resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined in equimolar quantities, heated at 70°C for ten minutes and slow cooled to allow annealing through their shared sequence in "linker
- 15 start" and "linker stop". In the third PCR step, primers "new start" and "new stop" are added to the annealed fragments to create and amplify the full-length new N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles
- 20 94°C denaturation for one minute, 60°C annealing for one minute and 72°C extension for one minute; plus one cycle 72°C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and
- 25 approximately 0.5 ug of DNA; and 1x PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl₂. PCR reactions are purified using a Wizard PCR Preps kit (Promega).
- 30 Method II. Creation of genes with new N-terminus/C-terminus without a linker region.

- New N-terminus/C-terminus genes without a linker joining the original N-terminus and C-terminus can be
- 35 made using two steps of PCR amplification and a blunt end ligation. The steps are illustrated in Figure 3. In the first step, the primer set ("new start" and "P-bl

start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein. In the second step, the primer set ("new stop" and "P-bl stop") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Stop") that contains the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include appropriate restriction sites which allow cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 50°C annealing for 45 seconds and 72°C extension for 45 seconds. Deep Vent polymerase (New England Biolabs) is used to reduce the occurrence of overhangs in conditions recommended by the manufacturer. The "P-bl start" and "P-bl stop" primers are phosphorylated at the end to aid in the subsequent blunt end ligation of "Fragment Start" and "Fragment Stop" to each other. A 100 ul reaction contained 150 pmole of each primer and one ug of template DNA; and 1x Vent buffer (New England Biolabs), 300 uM dGTP, 300 uM dATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT). PCR reaction products are purified using a Wizard PCR Preps kit (Promega).

The primers are designed to include appropriate restriction enzyme recognition sites which allow for the cloning of the new gene into expression vectors. Typically "Fragment Start" is designed to create a NcoI restriction site, and "Fragment Stop" is designed to create a HindIII restriction site. Restriction digest reactions are purified using a Magic DNA Clean-up System kit (Promega). Fragments Start and Stop are resolved on a 1% TAE gel, stained with ethidium bromide and isolated

using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined with and annealed to the ends of the ~ 3800 base pair NcoI/HindIII vector fragment of pMON3934 by heating at 50°C for ten minutes and allowed
5 to slow cool. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim). The result is a plasmid containing the full-length new N-terminus/C-terminus gene. A portion of the ligation reaction is used to transform *E. coli* strain DH5α cells (Life
10 Technologies, Gaithersburg, MD). Plasmid DNA is purified and sequence confirmed as below.

Method III. Creation of new N-terminus/C-terminus genes by tandem-duplication method

15

New N-terminus/C-terminus genes can be made based on the method described in R. A. Horlick, et al *Protein Eng.* 5:427-431 (1992). Polymerase chain reaction (PCR) amplification of the new N-terminus/C-terminus genes is
20 performed using a tandemly duplicated template DNA. The steps are illustrated in Figure 4.

The tandemly-duplicated template DNA is created by cloning and contains two copies of the gene separated by
25 DNA sequence encoding a linker connecting the original C- and N-terminal ends of the two copies of the gene. Specific primer sets are used to create and amplify a full-length new N terminus/C-terminus gene from the tandemly-duplicated template DNA. These primers are
30 designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 50°C annealing for one minute and 72°C
35 extension for one minute; plus one cycle 72°C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit (Perkin Elmer Corporation, Norwalk, CT) is

used. A 100 μ l reaction contains 100 pmole of each primer and one μ g of template DNA; and 1x PCR buffer, 200 μ M dGTP, 200 μ M dATP, 200 μ M dTTP, 200 μ M dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM $MgCl_2$. PCR

5 reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT). PCR reactions are purified using a Wizard PCR Preps kit (Promega).

10 DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. A few such methods

15 are shown herein. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, WI), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, 20 cells are pelleted by centrifugation (5000 x g), plasmid DNA released with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000 x g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the 25 column is washed, and plasmid DNA eluted with TE. After screening for the colonies with the plasmid of interest, the *E. coli* cells are inoculated into 50-100 mLs of LB plus appropriate antibiotic for overnight growth at 37°C in an air incubator while shaking. The purified plasmid 30 DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into mammalian, *E. coli* or other cells.

35 Sequence confirmation.

Purified plasmid DNA is resuspended in dH_2O and quantitated by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA

samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the
5 manufacturers suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions.
10 Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75%
15 polyacrylamide-8M urea gels using an ABI Model 373A automated DNA sequencer. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI).

20

Expression of flt3 receptor agonists in mammalian cells

Mammalian Cell Transfection/Production of Conditioned Media

25

The BHK-21 cell line can be obtained from the ATCC (Rockville, MD). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2mM (mM) L-glutamine and 10% fetal bovine serum
30 (FBS). This formulation is designated BHK growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (Calbiochem, San Diego, CA). The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which
35 transactivates the IE110 promoter found on the plasmid pMON3359 (See Hippenmeyer et al., *Bio/Technology*, pp.1037-1041, 1993). The VP16 protein drives expression

of genes inserted behind the IE110 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., *Poultry Sci.*, **70**: 970-981, 1991) expresses the
5 hygromycin resistance gene from the SV40 promoter. A similar plasmid is available from ATCC, pSV2-hph.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3×10^5 cells per dish 24 hours prior to transfection. Cells are transfected for 16
10 hours in 3 mL of "OPTIMEM"™ (Gibco-BRL, Gaithersburg, MD) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE"™ per dish. The media is subsequently aspirated and replaced
15 with 3 mL of growth media. At 48 hours post-transfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the dish by trypsin-EDTA, diluted 1:10 and transferred to 100 mm tissue culture dishes
20 containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked
25 in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

30

Expression of flt3 receptor agonists in *E. coli*

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37°C in M9 plus
35 casamino acids medium with shaking in a air incubator Model G25 from New Brunswick Scientific (Edison, New Jersey). Growth is monitored at OD600 until it reaches

a value of 1, at which time nalidixic acid (10 milligrams/mL) in 0.1 N NaOH is added to a final concentration of 50 µg/mL. The cultures are then shaken at 37°C for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al. Molecular Cloning: A Laboratory Manual, 1982). The culture is centrifuged (5000 x g) to pellet the cells. Additional strategies for achieving high-level expression of genes in *E. coli* can be found in Savvas, C.M. (*Microbiological Reviews* 60;512-538, 1996).

Inclusion Body preparation, Extraction, Refolding, Dialysis, DEAE Chromatography, and Characterization of the flt3 receptor agonists which accumulate as inclusion bodies in *E. coli*.

Isolation of Inclusion Bodies:

The cell pellet from a 330 mL *E. coli* culture is resuspended in 15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0 + 1 mM ethylenediaminetetraacetic acid (EDTA)). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, New York). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3

minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets:

Following the final centrifugation step, the IB pellet is resuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes to allow for denaturation of the expressed protein.

The extraction solution is transferred to a beaker containing 70 mL of 5mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred while exposed to air at 4°C for 18 to 48 hours to allow the proteins to refold. Refolding is monitored by analysis on a Vydac (Hesperia, Ca.) C18 reversed phase high pressure liquid chromatography (RP-HPLC) column (0.46x25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed to monitor the refold. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Denatured proteins generally elute later in the gradient than the refolded proteins.

Purification:

Following the refold, contaminating *E. coli* proteins are removed by acid precipitation. The pH of the refold solution is titrated to between pH 5.0 and pH 5.2 using 15% (v/v) acetic acid (HOAc). This solution is stirred at 4°C for 2 hours and then centrifuged for 20 minutes at 12,000 x g to pellet any insoluble protein.

The supernatant from the acid precipitation step is dialyzed using a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of 3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-fold excess) of 10mM

Tris-HCl, pH 8.0 for a total of 18 hours. Dialysis lowers the sample conductivity and removes urea prior to DEAE chromatography. The sample is then centrifuged (20 minutes at 12,000 x g) to pellet any insoluble protein following dialysis.

A Bio-Rad Bio-Scale DEAE2 column (7 x 52 mm) is used for ion exchange chromatography. The column is equilibrated in a buffer containing 10mM Tris-HCl, pH 8.0. The protein is eluted using a 0-to-500 mM sodium chloride (NaCl) gradient, in equilibration buffer, over 45 column volumes. A flow rate of 1 mL per minute is used throughout the run. Column fractions (2 mL per fraction) are collected across the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Ca.) C18 column (0.46 x 25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Pooled fractions are then dialyzed against 2 changes of 4 liters (50-to-500-fold excess) of 10 mM ammonium acetate (NH₄Ac), pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra/Por 3 membrane with a MWCO of 3,500 daltons. Finally, the sample is sterile filtered using a 0.22µm syringe filter (µStar LB syringe filter, Costar, Cambridge, Ma.), and stored at 4°C.

In some cases the folded proteins can be affinity purified using affinity reagents such as mAbs or receptor subunits attached to a suitable matrix. Alternatively, (or in addition) purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC.

These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 'Guide to Protein Purification' edited by Murray Deutscher, Academic Press, San Diego, CA (1990).

Protein Characterization:

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

Methylcellulose Assay

This assay reflects the ability of colony stimulating factors to stimulate normal bone marrow cells to produce different types of hematopoietic colonies *in vitro* (Bradley et al., *Aust. Exp Biol. Sci.* **44**:287-300, 1966), Pluznik et al., *J. Cell Comp. Physio* **66**:319-324, 1965).

20

Methods

Approximately 30 mL of fresh, normal, healthy bone marrow aspirate are obtained from individuals following informed consent. Under sterile conditions samples are diluted 1:5 with a 1X PBS (#14040.059 Life Technologies, Gaithersburg, MD.) solution in a 50 mL conical tube (#25339-50 Corning, Corning MD). Ficoll (Histopaque 1077 Sigma H-8889) is layered under the diluted sample and centrifuged, 300 x g for 30 min. The mononuclear cell band is removed and washed two times in 1X PBS and once with 1% BSA PBS (CellPro Co., Bothel, WA). Mononuclear cells are counted and CD34+ cells are selected using the Ceparate LC (CD34) Kit (CellPro Co., Bothel, WA) column. This fractionation is performed since all stem and progenitor cells within the bone marrow display CD34 surface antigen..

- Cultures are set up in triplicate with a final volume of 1.0 mL in a 35 X 10 mm petri dish (Nunc#174926). Culture medium is purchased from Terry Fox Labs. (HCC-4230 medium (Terry Fox Labs, Vancouver, B.C., Canada) and erythropoietin (Amgen, Thousand Oaks, CA.) is added to the culture media. 3,000-10,000 CD34+ cells are added per dish. FLT3 receptor agonist proteins, in conditioned media from transfected mammalian cells or purified from conditioned media from transfected mammalian cells or *E. coli*, are added to give final concentrations ranging from .001 nM to 10 nM. Cultures are resuspended using a 3cc syringe and 1.0 mL is dispensed per dish. Control (baseline response) cultures received no colony stimulating factors. Positive control cultures received conditioned media (PHA stimulated human cells: Terry Fox Lab. H2400). Cultures are incubated at 37°C, 5% CO₂ in humidified air. Hematopoietic colonies which are defined as greater than 50 cells are counted on the day of peak response (days 10-11) using a Nikon inverted phase microscope with a 40x objective combination. Groups of cells containing fewer than 50 cells are referred to as clusters. Alternatively colonies can be identified by spreading the colonies on a slide and stained or they can be picked, resuspended and spun onto cytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays

- Bone marrow cells are traditionally used for in vitro assays of hematopoietic colony stimulating factor (CSF) activity. However, human bone marrow is not always available, and there is considerable variability between donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer et al., *PNAS USA* **89**:4109-113,

1992; Mayani et al., *Blood* **81**:3252-3258, 1993). In contrast to bone marrow, cord blood is more readily available on a regular basis. There is also a potential to reduce assay variability by pooling cells obtained fresh from several donors, or to create a bank of cryopreserved cells for this purpose.

Methods

Mononuclear cells (MNC) are isolated from cord blood within 24 hr. of collection, using a standard density gradient (1.077 g/mL Histopaque). Cord blood MNC have been further enriched for stem cells and progenitors by several procedures, including immunomagnetic selection for CD14-, CD34+ cells; panning for SBA-, CD34+ fraction using coated flasks from Applied Immune Science (Santa Clara, CA); and CD34+ selection using a CellPro (Bothell, WA) avidin column. Either freshly isolated or cryopreserved CD34+ cell enriched fractions are used for the assay. Duplicate cultures for each serial dilution of sample (concentration range from 1 pM to 1204 pM) are prepared with 1x10⁴ cells in 1ml of 0.9% methylcellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies, Vancouver, BC.). In some experiments, Methocult H4330 containing erythropoietin (FLT3) was used instead of Methocult H4230, or Stem Cell Factor (SCF), 50 ng/mL (Biosource International, Camarillo, CA) was added. After culturing for 7-9 days, colonies containing >30 cells are counted.

MUTZ-2 Cell Proliferation Assay

A cell line such as MUTZ-2, which is a human myeloid leukemia cell line (German Collection of Microorganisms and Cell Cultures, DSM ACC 271), can be used to determine the cell proliferative activity of flt3 receptor agonists. MUTZ-2 cultures are maintained with recombinant native flt3 ligand (20-100ng/mL) in the

growth medium. Eighteen hours prior to assay set-up, MUTZ-2 cells are washed in IMDM medium (Gibco) three times and are resuspended in IMDM medium alone at a concentration of $0.5-0.7 \times 10^6$ cells/mL and incubated at 37°C and 5%CO₂ to starve the cells of flt3 ligand. The day of the assay, standards and flt3 receptor agonists are diluted to two fold above desired final concentration in assay media in sterile tissue culture treated 96 well plates. Flt3 receptor agonists and standards are tested in triplicate. 50µl of assay media is loaded into all wells except row A. 75µl of the flt3 receptor agonists or standards are added to row A and 25µl taken from that row and serial dilutions (1:3) performed on the rest of the plate (rows B through G). Row H remains as a media only control. The starved MUTZ-2 cells are washed two times in IMDM medium and resuspended in 50µl assay media. 50µl of cells are added to each well resulting in a final concentration of 0.25×10^6 cells/mL. Assay plates containing cells are incubated at 37°C and 5%CO₂ for 44hrs. Each well is then pulsed with 1µCi/well of tritiated thymidine in a volume of 20µl for four hours. Plates are then harvested and counted.

25 Transfected cell lines:

Cell lines, such as BHK or the murine pro B cell line Baf/3, can be transfected with a colony stimulating factor receptor, such as the human flt3 receptor which the cell line does not have. These transfected cell lines can be used to determine the activity of the ligand of which the receptor has been transfected.

EXAMPLE 1

35

Isolation of cDNA encoding flt3 ligand

Three flt3 ligand clones were amplified from human bone marrow poly A+ RNA (Clontech) using NCOFLT, HIND160, and HIND165 PCR primers (according to the manufacturer's suggested conditions). These amplified PCR products were gel purified and cloned into the BHK expression vector pMON5723 generating pMON30237 (NCOFLT + HIND160), pMON30238 (NCOFLT + HIND165), and a deletion clone pMON30239 (NCOFLT + HIND165). The deletion in pMON30239 is of amino acid residues 89 through 106 (the numbering of the residues is based on the sequence of native flt3 ligand as shown in Figure 5a and 5b).

EXAMPLE 2

Sequence rearranged flt3 ligand were constructed using several methods and linker types. The first set of constructs containing the linker peptide (SerGlyGlyAsnGly)X (where X = 1, 2, or 3) with the breakpoints 39/40, 65/66, and 89/90 were made using a two step PCR process described by Mullins et al. in which the front half and the back half of each final sequence rearranged molecule is made separately in the first PCR step, then the paired products of the first reaction step are combined in a second PCR step and extended in the absence of exogenous primers. For example, to make the three 89/90 breakpoint precursor molecules with the SerGlyGlyAsnGly SEQ ID NO:46, SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:47, and SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:48 amino acid linkers (pMON32326, pMON32327 and pMON32328 respectively), six initial PCR products were generated. The following primer pairs were used in the first step PCR reaction: a) 89For/L5B; b) 89For/L10B; c) 89For/L15B; d) 89Rev/L5A; e) 89Rev/L10A; and f) 89Rev/L15A. The identical approach was used to make pMON32321 (39/40 breakpoint, primer pairs 39For/L10B and

39Rev/L10A) and pMON32325 (65/66 breakpoint, primer pairs 65For/L5B and 65Rev/L5A) precursors. Except as noted below, all subsequent PCR reactions utilized the components of the PCR Optimizer Kit (Invitrogen) and amplification conditions according to the manufacturers suggested protocol. Reactions were set up as follows: 50 pmole of each primer, 10 ul of 5X Buffer B [300 mM Tris-HCl (pH 8.5), 10 mM MgCl₂, 75 mM (NH₄)₂SO₄], 5 U Taq polymerase, and 100 ng of heat denatured DNA (in this example pMON30238) template were combined, and brought to 45 ul final volume with dH₂O. Reactions were pre-incubated for 1-5 minute at 80°C, then 5 ul of 10 mM dNTP added to each reaction, and heat denatured for 2 minutes at 94°C prior to amplification in a Perkin Elmer model 480 DNA thermal cycler. Seven DNA amplification cycles were done under the following conditions: heat denature for one minute at 94°C, two minutes annealing at 65°C, followed by a three minute extension at 72°C. Twenty three additional cycles consisting of a one minute heat denaturation at 94°C followed by a four minute annealing/extension at 72°C were done, followed by a final 7 minute extension cycle at 72°C. With the exception of pMON32328, the PCR amplification products were run out on a 1.2% TAE agarose gel, and the appropriate size bands (the major amplification product) were excised and purified using Geneclean II (Bio 101). Samples were resuspended in 10 ul dH₂O. The amplification products for pMON32328 were purified directly using a Wizard PCR Clean UP kit (Promega), and DNA eluted in 50 ul dH₂O.

The method to construct the precursors of pMON32322 (39/40 breakpoint, primer pairs 39For/L5B and 39Rev/L5A) was modified by increasing the amount of template to 1 ug, and by changing the PCR amplification conditions as follows: six cycles of 94°C, 1 minute, 65°C for 2 minute, and 72°C for 2 1/2 minutes, followed by 15 cycles of 94°C for 1 minute, 70°C for 2 minutes, and

72°C for 2 minutes, followed by a single 72°C extension cycle for seven minutes.

The second PCR step utilized the gel-purified precursors from the first PCR step as a combination of

- 5 primer/template as follows: 5 ul each of each precursor molecule (i.e. for pMON32328 the PCR products from primer pairs 89For/L5B and 89Rev/L5A), 10 ul of 5X Buffer B, 5 U of Taq polymerase, and 24 ul dH₂O. The reactions were heated for five minutes at 80°C, 5 ul of
- 10 10 mM dNTP was added, and the reactions heat denatured for 94°C for two minutes. DNA amplification conditions were as follows: 15 cycles of 94°C for one minute, 69°C for two minutes, followed then by a three minute extension at 72°C. To allow for complete extension, the
- 15 last cycle was followed by a single extension step at 72°C for seven minutes. The 80 deg incubation time was reduced to two minutes and the number of cycles was decreased to ten cycles for pMON32325 (PCR products 65For/L5B and 65Rev/L5A). PCR reaction products of the
- 20 appropriate size were gel purified on a 1.2 % TAE agarose gel using Geneclean II. For pMON32322 (39For/L5B and 39Rev/L5A) the annealing temperature was reduced to 68°C, and the extension time reduced to two minutes. In addition, the PCR product was purified using a Wizard
- 25 PCR Clean Up kit (Promega) according to the suppliers suggested protocol. The second PCR step was modified for pMON32326 (PCR products of 89For/L15B and 89Rev/L15A) as follows. Three sets of PCR reactions were set up identically as above, except for the sample
- 30 buffer type (either 5X buffer B, D, or J - PCR Optimizer Kit). Composition of buffers D and J differ from buffer B only by pH or [MgCl₂]. The [MgCl₂] for buffer D is 3.5 mM, whereas the pH of buffer J is 9.5. The protocol was modified by increasing the number of PCR cycles 20,
- 35 and 15 ul aliquots were withdrawn at the end of cycles 10, 15 and 20. Five uls of each aliquot timepoint were analyzed for the presence of amplified material on a

1.2% TBE agarose gel. The remainder of the buffer B, D, and J PCR reaction mixtures were pooled and subsequently purified using the Wizard PCR Clean Up Kit protocol. The DNA was eluted in 50 ul dH₂O.

5

The purified samples from the second step PCR reaction were digested with NcoI/HindIII using one of two standardized digestion conditions. For Geneclean II purified samples, 10 ul of DNA were digested in a 20 ul reaction with 7.5 U each of NcoI/HindIII for two hours at 37°C, and gel purified on a 1.1% TAE agarose gel again with Geneclean II. Ligation-ready samples were resuspended in 10 ul dH₂O. For pMON32322, 20 ul of sample was digested in a 50 ul reaction volume with 20U each of NcoI and HindIII for 3 hour at 37°C. 0.1 volume 3M NaOAc (pH 5.5) and 2.5 volume of EtOH were added, mixed, and stored at -20°C overnight. The DNA was recovered by pelleting for 20 minutes at 13,000 rpm @ 4°C in a Sigma Mk 202 microfuge. The DNA pellet was rinsed with chilled 70% EtOH, lyophilized, and resuspended in 10 ul dH₂O.

EXAMPLE 3

25 An alternate approach was used to construct pMON32320 (39/40 breakpoint, fifteen amino acid linker), pMON32323 (65/66 breakpoint, fifteen AA linker), and pMON32324 (65/66 breakpoint, ten amino acid linker). New primers (L15C, L15D, L15E) were designed to incorporate BamHI
30 restriction site in the primer that was inframe to allow cloning into the BamHI site and maintain the proper reading frame. PCR reaction conditions for the first step were performed identically to that described for pMON32322, except that the following set of primer pairs
35 were used: 65For/L15D and 65Rev/L15E (pMON32324); 39For/L15D and 39Rev/L15C (pMON32320); and 65For/L15D and 65Rev/L15C (pMON32323). The PCR reaction products

were purified using a Wizard PCR Clean Up kit as described, and eluted in 50 ul dH₂O. Samples were digested with either NcoI/BamHI (39For/L15D and 65For/L15D) or BamHI/HindIII (39Rev/L15C, 65Rev/L15C, and 65Rev/L15E). Restriction digests were performed as follows: 10 ul of purified PCR reaction products, 3 ul of 10X universal restriction buffer, 15 U of either NcoI or HindIII, 15 U of BamHI, in a final reaction volume of 30 ul. Reactions were incubated for 90 minutes at 37°C, and the PCR products gel purified on a 1.1% TAE agarose gel using GeneClean II. Ligation-ready DNA was resuspended in 10 ul dH₂O.

Inserts were ligated to NcoI/ HindIII digested pMON3977 (BHK mammalian expression vector) that had been treated with shrimp alkaline phosphatase (SAP) either in a three way (pMON32320, pMON32323, or pMON32324) or a two way (pMON32321, pMON32322, pMON32325, pMON32326, pMON32327 and pMON32328) ligation reaction as follows: 2.5 ul of insert (2 ul of each primer pair amplicon for pMON32320, pMON32323, and pMON32324) was added to 50 ng of vector in a ten ul reaction using standard ligation conditions. Two ul of each reaction was transformed with 100 ul of chemically competent DH5α cells (Gibco/BRL) following the manufacturers suggested protocol. Twenty five ul and 200 ul aliquots were plated out on LB plates containing 50 ug/mL ampicillin and incubated overnight. Isolated colonies were picked and DNA prepared from 50 mL overnight cultures using Qiagen DNA midiprep kits. DNA was quantitated by absorbance at A260/A280, and verified for correct insert size by agarose gel electrophoresis following digestion of 1 ug template with NcoI/HindIII restriction endonucleases. Samples containing inserts of the predicted size were sequenced in both orientations using vector-specific primers using an automated fluorescent DNA sequencer model 373A (Perkin Elmer ABI). Sequencing

reactions were done in 20 ul reaction volumes using a Perkin Elmer model 480 DNA thermal cycler as follows: one ug of template, 3.2 pmole primer, 1 ul DMSO, 9.5 ul Taq terminator dyedexoxy premix (Perkin Elmer ABI) were
5 combined, and subjected to 25 cycles of sequencing amplification as follows: 30 seconds at 94°C, 15 second annealing at 50°C, followed by a four minute extension cycle at 60°C. Samples were purified using Centri-Sep spin columns (Princeton Separations) following the
10 manufacturers suggested protocol, lyophilized, and submitted for sequence analysis. Samples containing the predicted amino acid sequence were selected for analysis and assigned pMONnumbers.

15

EXAMPLE 4

A similar approach used to construct pMON32320, pMON32323, and pMON32324 was utilized to introduce the second linker type (SerGlyGlySerGly)X where x = 2 or 3,
20 into two sequence rearranged flt3 receptor agonists containing the 39/40 breakpoint (pMON32348 and 32350). The primer pairs were as follows: for pMON32348 the combinations of 339For2/339Rev3 and 339Rev2/339-10For3 and for pMON32350 the combinations of 339For2/339Rev3
25 and 339Rev2/339-15For3 were used to create three PCR amplification products. Each PCR amplification was set up as follows: to 100 ng of heat denatured pMON32320, 50 pmole of each primer pair, 10 ul of 5X Buffer B, 5 U of Taq polymerase and dH₂O was added to a final volume of
30 45 ul. Reactions were pre-incubated as described before. Fifteen amplification cycles were done under the following conditions: heat denature at 94°C, one minute, followed by a two minute annealing step at 70°C, and a three minute extension at 72°C. After the last
35 cycle, a single 72 deg extension step of 7 minutes was done. The PCR amplification products of primer pairs 339For2/339Rev3, 339Rev2/339-10For3, and 339Rev2/339-15For2 were purified using a Wizard PCR Clean Up kit

(Promega), and eluted in 50 ul dH₂O. NcoI/BamHI digests for the 339For2/339Rev3 primer pair as follows: 8 ul of DNA template was mixed with 2 ul universal restriction buffer and 10 U each of NcoI and BamHI in a 20 ul reaction volume, and incubated for 90 minutes at 37°C. The digestion products was purified using the Geneclean II direct purification protocol, and ligation ready DNA resuspended in 10 ul dH₂O. The restriction digests and subsequent purification for the 339Rev2/339-10For3 and 339Rev2/339-15For2 amplification products were done identically as described for the 339For2/339Rev3 amplicon, except that 10 U of HindIII was substituted for NcoI. Standard ligations were done by adding to 50 ng NcoI/HindIII/SAP-treated, gel purified pMON3977, 0.5 ul 339For2/Rev3 amplicon, 1 ul of either 339Rev2/339-10For3 (pMON32348) or 339Rev2/339-15For3 (pMON32350) amplicons, 5U T4 DNA ligase, and 1 ul 10 X ligase buffer in a 10 ul reaction volume for 60 minutes at ambient temperature. Subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 5

A third type of linker, with a variable (GlyGlyGlySer)_X repeat motif, was incorporated into another set of sequence rearranged flt3 receptor agonists from modularly constructed templates. These linker lengths were;

6 AA linker (GlyGlyGlySerGlyGly SEQ ID NO:51),
7 AA linker (GlyGlyGlySerGlyGlyGly SEQ ID NO:52),
10 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:53),
13 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGlySerGlyGly SEQ ID NO:54),

15 AA linker
(GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID
NO:55); and
21 AA linker

5 (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
GlySerGly SEQ ID NO:56) amino acid residues. These modular
templates, each comprising a dimer of hflt3 ligand
separated by a BamHI-containing linker of unique length,
were constructed as follows. Six intermediate PLASMID
10 templates, FL3N, FL7N, FL11N, FL3C, FL4C, and FL10C,
were constructed by PCR using paired primers and
pMON30238 as template using cycling conditions similar
to those employed for pMON32322. Per reaction, 50 pmole
of each primer was added to 100 ng of heat-denatured
15 template and the reactions assembled as described for
pMON32322. Cycle conditions were as follows: seven
cycles of 94°C, one minute; two minutes at 65°C, and 2.5
minutes at 72°C; followed by ten cycles of one minute at
94°C, two minutes at 70°C, and 2.5 minutes at 72°C. A
20 single seven minute extension at 72°C completed the
cycling reactions. The primer pairs used to construct
each intermediate were; N-term/FLN3 (FL3N); N-term/FLN7
(FL7N); N-term/FLN11 (FL11N); C term/FLC3 (FL3C); C-
term/FLC4 (FL4C); and C-term/FLC10 (FL10C). The PCR
25 amplification products were purified with Wizard PCR
Clean Up kits (Promega) and eluted in 50 ul dH₂O.
Purified DNA for the first subset, FL3N, FL7N, and
FL11N, were digested with NcoI/BamHI, gel purified as
described previously, and ligated to NcoI/BamHI/Sap-
30 treated pSE420 vector DNA (Invitrogen). Intermediate
templates of the second subset, FL3C, FL4C, and FL10C,
were constructed in an identical manner except HindIII
was utilized instead of NcoI. Subsequent steps leading
to final DNA sequence confirmation were done as
35 described above.

EXAMPLE 6

To make the next six templates, the two subsets of intermediates in pSE420 were digested with either NcoI/BamHI (FL3N, FL7N, FL11N-subset 1) or BamHI/HindIII (FL3C, FL4C, FL10C-subset 2) and gel purified using Geneclean II as described previously. One intermediate amplicon from each subset were ligated to NcoI/HindIII/SAP-treated pMON3977 per reaction and transformed in DH5 α cells as described previously using the following combinations to generate specific linker lengths: six AA linker (FL3N and FL3C), seven AA linker (FL3N and FL4C), ten AA linker (FL7N and FL3C), thirteen AA linker (FL3N and FL10C), fifteen AA linker (FL11N and FL4C), and 21 AA linker (FL11N and FL10C). DNA was prepared 50 mL overnight cultures from single colonies from each of the six combination as described above, analyzed for correct insert size by NcoI/HindIII restriction analysis, and used as template. Primer pairs 39For/39Rev (39/40 breakpoint); 65For/65Rev (65/66 breakpoint) and 89For/89Rev (89/90 breakpoint) were used to PCR amplify each templates as described for pMON32322, except 75 pmole of each primer was used. Amplification conditions were modified as follows: six cycles of 94°C for one minute, 2 minutes at 70°C, 2.5 minutes at 72°C; followed by nine cycles of 94°C for one minute, and three minutes at 72°C. After the last cycle, a final extension of six minutes at 72°C allowed ample time for full extension of products. Samples were purified using a Wizard PCR Clean Up kit as described, and double digested with NcoI/HindIII. These amplification products were purified again using a Wizard PCR Clean Up kit. In addition, all six different linker length molecules for the 39/40 breakpoint were cloned into NcoI/HindIII/SAP-treated pMON3977 as single proteins (pMON32365, pMON32366, pMON32367, pMON32368, pMON32369 and 32370). Subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 7

Additional sequence rearranged Flt3 ligands were
5 constructed using the dimer template intermediates
previously described. For sequence rearranged Flt3
ligands having the fifteen amino acid linker
(GlyGlyGlySer)₃GlyGlyGly SEQ ID NO:55, the dimer
intermediates Flt4C.seq and Flt11N.seq were used as the
10 template in the PCR reaction. Five new breakpoints
corresponding to Flt3 ligand amino acid residues 28/29,
34/35, 62/63, 94/95, and 98/99, were constructed using a
PCR based approach using a PCR Optimizer kit
(Invitrogen) and the following primer pairs;
15 FL29For/FL29Rev, FL35For/FL35Rev, FL63For/FL63Rev,
FL95For/FL95Rev, FL99For/FL99Rev. Amplification
conditions were as follows: seven cycles of 94°C for 1',
62°C for 2', and 2.5' at 70°C; twelve cycles of 94°C for
1', 68°C for 2', and 70°C for 2.5'; followed by a final
20 cycle of 7' at 72°C. PCR products corresponding to the
predicted insert size were digested to completion with
NcoI and HindIII, and gel purified as described
previously using Gene Clean II (Bio 101) following the
manufacturers suggested protocol. Samples were
25 resuspended in 10 ul final volume with dH₂O. Inserts
were cloned as single genes into the mammalian
expression vector pMON3977 (NcoI/HindIII/SAP treated)
and designated pMON35712, pMON35713, pMON35714,
pMON35715, pMON35716, pMON35717, pMON35718 respectively.
30

Additional techniques for the construction of the
variant genes, recombinant protein expression, protein
35 purification, protein characterization, biological
activity determination can be found in WO 94/12639, WO
94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO

95/21254 and WO 96/23888 which are hereby incorporated by reference in their entirety.

5 All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.

10 Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

15

With reference to the use of the word(s) "comprise" or "comprises" or "comprising" in the foregoing description and/or in the following claims, we note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and
20 that we intend each of those words to be so interpreted in construing the foregoing description and/or the following claims.



SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: G.D. Searle Corporate Patent Department
- (ii) TITLE OF THE INVENTION: Novel flt3 Receptor Agonists
- (iii) NUMBER OF SEQUENCES: 151
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: G. D. Searle Corporate Patent Department
 - (B) STREET: P.O. Box 55110
 - (C) CITY: Chicago
 - (D) STATE: IL
 - (E) COUNTRY: USA
 - (F) ZIP: 60680
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 21-OCT-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/030,094
 - (B) FILING DATE: 25-OCT-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Bennett, Dennis A
 - (B) REGISTRATION NUMBER: 34,547
 - (C) REFERENCE/DOCKET NUMBER: C-2993/2
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 314-737-6986
 - (B) TELEFAX: 314-737-6972
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 135 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
 1           5           10           15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
 20           25           30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Ala Leu
 35           40           45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
 50           55           60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
 65           70           75           80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg
 85           90           95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
100          105          110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
115          120          125
Leu Glu Leu Gln Cys Gln Pro

```

130

135

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
20     25     30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu
35     40     45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
50     55     60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
65     70     75     80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg
85     90     95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
100    105    110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
115    120    125
Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
130    135    140

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 122 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
20     25     30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu
35     40     45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
50     55     60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
65     70     75     80
His Phe Val Thr Lys Cys Ala Phe Gln Glu Thr Ser Glu Gln Leu Val
85     90     95
Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu
100    105    110
Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
115    120

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 135 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro

```

```

      20      25      30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu
      35      40      45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
      50      55      60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
      65      70      75      80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg
      85      90      95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
      100      105      110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
      115      120      125
Leu Glu Leu Gln Cys Gln Pro
      130      135

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
      20      25      30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu
      35      40      45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
      50      55      60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
      65      70      75      80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg
      85      90      95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
      100      105      110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
      115      120      125
Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
      130      135      140

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 135 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
      20      25      30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu
      35      40      45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
      50      55      60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
      65      70      75      80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg
      85      90      95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
      100      105      110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
      115      120      125
Leu Glu Leu Gln Cys Gln Pro
      130      135

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe
 1      5      10      15
Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro
 20      25      30
Val Thr Val Ala Ser Asn Leu Gln Asp Glu Leu Cys Gly Gly Leu
 35      40      45
Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val
 50      55      60
Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile
 65      70      75      80
His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg
 85      90      95
Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln
100      105      110
Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys
115      120      125
Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
130      135      140

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85      90      95
Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser
100      105      110
Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser
115      120      125
Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln
130      135      140
Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln
145      150      155

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85      90      95
Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr
100      105      110
Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val
115      120      125
Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr
130      135      140
Val Ala Ser Asn Leu Gln
145      150

```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85      90      95
Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe
100      105      110
Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
115      120      125
Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
130      135      140
Gln
145

```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
 1      5      10      15
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
 20      25      30
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
 35      40      45
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
 50      55      60
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly
 65      70      75      80
Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe

```

```

      85          90          95
Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
      100          105          110
Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
      115          120          125
Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
      130          135          140
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly
      145          150          155

```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
1      5      10      15
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg Phe
      20      25      30
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
      35      40      45
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
      50      55      60
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly
      65      70      75      80
Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile
      85      90      95
Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu
      100      105      110
Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu
      115      120      125
Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg
      130      135      140
Leu Lys Thr Val Ala Gly
      145      150

```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
1      5      10      15
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Ser Cys Leu Arg Phe
      20      25      30
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
      35      40      45
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
      50      55      60
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly
      65      70      75      80
Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala
      85      90      95
Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val
      100      105      110
Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp
      115      120      125
Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala
      130      135      140
Gly
      145

```

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```

Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu
 1          5          10
Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr
 20          25          30
Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser
 35          40          45
Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly
 50          55          60
Asn Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
 65          70          75
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
 85          90          95
Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly
100          105          110
Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
115          120          125
Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu
130          135          140
Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro
145          150          155

```

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu
 1          5          10
Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr
 20          25          30
Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser
 35          40          45
Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gln Asp
 50          55          60
Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile
 65          70          75
Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala
 85          90          95
Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val
100          105          110
Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys
115          120          125
Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr
130          135          140
Lys Cys Ala Phe Gln Pro
145          150

```

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 145 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu
1      5      10      15
Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr
20      25      30
Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser
35      40      45
Ser Thr Leu Ser Gly Gly Asn Gly Thr Gln Asp Cys Ser Phe Gln His
50      55      60
Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp
65      70      75      80
Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp
85      90      95
Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp
100     105     110
Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly Leu Leu
115     120     125
Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln
130     135     140
Pro
145

```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
85      90      95
Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser
100     105     110
Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser
115     120     125
Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln
130     135     140
Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln
145     150     155

```

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro

```

```

      85          90          95
Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Thr
      100      105      110
Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val
      115      120      125
Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr
      130      135      140
Val Ala Ser Asn Leu Gln
      145      150

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
1      5      10      15
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
20      25      30
Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly
35      40      45
Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
50      55      60
Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu
65      70      75      80
Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu
85      90      95
Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu
100      105      110
Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg
115      120      125
Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly
130      135      140
Ser
145

```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 143 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

Gly Ser Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser
1      5      10      15
Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln
20      25      30
Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys
35      40      45
Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu
50      55      60
Lys Thr Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn
65      70      75      80
Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser
85      90      95
Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr
100      105      110
Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe
115      120      125
Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
130      135      140

```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

90

- (A) LENGTH: 149 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
 1           5           10           15
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
 20           25           30
Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly
 35           40           45
Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
 50           55           60
Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu
 65           70           75
Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu
 85           90           95
Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu
100           105           110
Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg
115           120           125
Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly
130           135           140
Ser Gly Gly Gly Ser
145
  
```

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 144 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile
 1           5           10           15
Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu
 20           25           30
Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu
 35           40           45
Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg
 50           55           60
Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val
 65           70           75
Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro
 85           90           95
Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu
100           105           110
Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn
115           120           125
Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
130           135           140
  
```

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 153 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Met Ala Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
 1           5           10           15
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
 20           25           30
  
```

```

Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly
   35           40           45
Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
   50           55           60
Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu
   65           70           75           80
Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu
   85           90           95
Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu
  100           105           110
Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg
  115           120           125
Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly
  130           135           140
Ser Gly Gly Gly Ser Gly Gly Ser
  145           150

```

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser
   1           5           10           15
Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu
  20           25           30
Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn
  35           40           45
Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala
  50           55           60
Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln
  65           70           75           80
Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys
  85           90           95
Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile
 100           105           110
Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro
 115           120           125
Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln
 130           135           140
Pro Asp Ser Ser Thr Leu
 145           150

```

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 146 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
   1           5           10           15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
  20           25           30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
  35           40           45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
  50           55           60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
  65           70           75           80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
  85           90           95
Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gln Asp Cys Ser
 100           105           110
Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu

```

115 120 125
 Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn
 130 135 140
 Leu Gln
 145

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1 5 10 15
 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20 25 30
 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35 40 45
 Phe Gln Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50 55 60
 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65 70 75 80
 Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85 90 95
 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Asp Cys
 100 105 110
 Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg
 115 120 125
 Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser
 130 135 140
 Asn Leu Gln
 145

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1 5 10 15
 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20 25 30
 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35 40 45
 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50 55 60
 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65 70 75 80
 Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85 90 95
 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr
 100 105 110
 Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val
 115 120 125
 Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr
 130 135 140
 Val Ala Ser Asn Leu Gln
 145 150

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 153 amino acids
 (B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85      90      95
Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
100      105      110
Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
115      120      125
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
130      135      140
Pro Val Thr Val Ala Ser Asn Leu Gln
145      150

```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 155 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 35      40      45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 50      55      60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 65      70      75      80
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 85      90      95
Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
100      105      110
Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser
115      120      125
Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln
130      135      140
Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln
145      150      155

```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 161 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 1      5      10      15
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 20      25      30

```

```

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
   35           40           45
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
   50           55           60
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
   65           70           75
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
   85           90           95
Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
  100           105           110
Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gln Asp Cys Ser Phe
  115           120           125
Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
  130           135           140
Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
  145           150           155
Gln

```

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```

Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu
   1           5           10           15
Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg
  20           25           30
Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val
  35           40           45
Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro
  50           55           60
Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu
  65           70           75
Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn
  85           90           95
Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
 100           105           110
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr
 115           120           125
Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val
 130           135           140
Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln
 145           150           155

```

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

```

Ala Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg
   1           5           10           15
Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly
  20           25           30
Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe
  35           40           45
Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val
  50           55           60
Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val
  65           70           75
Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu
  85           90           95
Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

```

```

      100      105      110
Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln
      115      120      125
His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser
      130      135      140
Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val
      145      150      155

```

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

Ala Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr
 1      5      10      15
Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys
 20      25      30
Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser
 35      40      45
Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser
 50      55      60
Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly
 65      70      75      80
Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp
 85      90      95
Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile
100      105      110
Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala
115      120      125
Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val
130      135      140
Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
145      150      155

```

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

Ala Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
 1      5      10      15
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
 20      25      30
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
 35      40      45
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
 50      55      60
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Ser Gly
 65      70      75      80
Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe
 85      90      95
Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
100      105      110
Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
115      120      125
Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
130      135      140
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly
145      150      155

```

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

Ala Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu
 1          5          10          15
Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr
 20          25          30
Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser
 35          40          45
Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
 50          55          60
Gly Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp
 65          70          75
Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr
 85          90          95
Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly
100          105          110
Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr
115          120          125
Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu
130          135          140
Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro
145          150          155
  
```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```

Ala Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser
 1          5          10          15
Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser
 20          25          30
Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly
 35          40          45
Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp
 50          55          60
Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile
 65          70          75
Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala
 85          90          95
Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val
100          105          110
Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys
115          120          125
Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr
130          135          140
Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu
145          150          155
  
```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

```

Ala Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val
 1          5          10          15
  
```

Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu
 20 25 30
 Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly
 35 40 45
 Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gln Asp Cys Ser Phe Gln
 50 55 60
 His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu Ser
 65 70 75 80
 Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gln
 85 90 95
 Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln Arg
 100 105 110
 Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly Leu
 115 120 125
 Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala Phe
 130 135 140
 Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln
 145 150 155

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Gly Gly Gly Ser
 1

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Gly Gly Gly Ser Gly Gly Gly Ser
 1 5

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1 5 10

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Ser Gly Gly Ser Gly Gly Ser

1

5

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Glu Phe Gly Asn Met
1 5

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Glu Phe Gly Gly Asn Met
1 5

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Glu Phe Gly Gly Asn Gly Gly Asn Met
1 5

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Gly Gly Ser Asp Met Ala Gly
1 5

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Ser Gly Gly Asn Gly
1 5

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Gly Gly Gly Ser Gly Gly
1 5

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Gly Gly Gly Ser Gly Gly Gly
 1 5

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Gly Gly Gly Ser Gly Gly Ser Gly Gly
 1 5 10

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly
 1 5 10

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1 5 10 15
 Gly Gly Gly Ser Gly
 20

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

CTGACCATGG CNACCCAGGA CTGCTCCTTC CAA

33

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

ACTGAAGCTT AGGGCTGACA CTGCAGCTCC AG

32

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ACTGAAGCTT ACAGGGTGA GGAGTCGGGC TG

32

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC

46

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC

46

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

TGTCCTAACT CATCAATGTA TC

22

(2) INFORMATION FOR SEQ ID NO:63:

102

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

CATGGCCATG GCCGACGAGG AGCTCTGCGG GGGCCTCT 38

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GCTAGAAGCT TACTGCAGGT TGGAGGCCAC GGTGAC 36

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

CATGGCCATG GCCTCCAAGA TGCAAGGCTT GCTGGAGC 38

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GCTAGAAGCT TACCCAGCGA CAGTCTTGAG CCGCTC 36

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CATGGCCATG GCCCCCCCA GCTGTCTTCG CTTCTG 36

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GCTAGAAGCT TAGGGCTGAA AGGCACATTT GGTGACA 37

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

CCCTGTCTGG CGGCAACGGC ACCCAGGACT GCTCCTTCCA AC 42

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GCGGTAACGG CAGTGGAGGT AATGGCACCC AGGACTGCTC CTTCACAC 48

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 57 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

ACGGCAGTGG TGGCAATGGG AGCGGCGGAA ATGGAACCCA GGACTGCTCC TTCCAAC 57

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

GTGCCGTTGC CGCCAGACAG GGTGAGGAG TCGGGCTG 38

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

ATTACCTCCA CTGCCGTTAC CGCCTGACAG GGTGAGGAG TCGGGCTG 48

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

GCTCCCATG CCACCACTGC CGTTACCTCC AGACAGGGTT GAGGAGTCGG GCTG 54

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

GATGAGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCACC 60

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GATGACGGAT CCGTTACCTC CAGACAGGT TGAGGAGTCG GGCTG 45

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

GATGACGGAT CCGGAGGTAA TGGCACCCAG GACTGCTCCT TCCAAC 46

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

GACTGCCATG GCCGACGAGG AGCTCTGCG 29

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

GACTCAAGCT TACTGCAGGT TGGAGGCC 28

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GACTCGGGAT CCGGAGGTTT TGGCACCCAG GACTGCTCC 39

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

GACTGGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC C 41

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

GACTTGGGAT CCACTACCTC CAGACAGGGT TGAGGAGTC 39

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

ACTGACGGAT CCACCGCCCA GGGTTGAGGA GTCGGGCTG 39

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

ACTGACGGAT CCACCTCCTG ACCCACC GCC CAGGGTTGAG GAGTCGGGCT G 51

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

ACTGACGGAT CCACCTCCTG ACCCACCCTC TGACCCACCG CCCAGGGTTG AGGAGTCGGG 60
CTG 63

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:
ACGTAAAGCT TACAGGGTTG AGGAGTCG 28
(2) INFORMATION FOR SEQ ID NO:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:
GTCAGTGGAT CCGGAGGTAC CCAGGACTGC TCCTTCCAAC 40
(2) INFORMATION FOR SEQ ID NO:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
GTCAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AAC 43
(2) INFORMATION FOR SEQ ID NO:89:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:
GTCAGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAC 60
(2) INFORMATION FOR SEQ ID NO:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:
GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57
(2) INFORMATION FOR SEQ ID NO:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:
GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGCTC 57
(2) INFORMATION FOR SEQ ID NO:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:
GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGCCGGCT GGTCTCTG 57
- (2) INFORMATION FOR SEQ ID NO:93:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:
GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GCGGCTGGT CCTGGCA 57
- (2) INFORMATION FOR SEQ ID NO:94:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:
GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCTT GGCACAG 57
- (2) INFORMATION FOR SEQ ID NO:95:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:
GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGCCGGC TGGTCTCTGC ACAGCGC 57
- (2) INFORMATION FOR SEQ ID NO:96:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:
GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57
- (2) INFORMATION FOR SEQ ID NO:97:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:
GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCAGCG CTGGATG 57
- (2) INFORMATION FOR SEQ ID NO:98:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:
TATGCAAGCT TAGGCCACGG TGACTGGGTA 30
(2) INFORMATION FOR SEQ ID NO:99:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:
TATGCAAGCT TAGGAGGCCA CGGTGACTGG 30
(2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
TATGCAAGCT TAGTTGGAGG CCACGGTGAC 30
(2) INFORMATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
TATGCAAGCT TACAGGTTGG AGGCCACGGT 30
(2) INFORMATION FOR SEQ ID NO:102:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:
TATGCAAGCT TACTGCAGGT TGGAGGCCAC 30
(2) INFORMATION FOR SEQ ID NO:103:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:
TATGCAAGCT TAGTCCTGCA GGTGGAGGC 30
(2) INFORMATION FOR SEQ ID NO:104:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

TATGCAAGCT TACTCGTCCT GCAGGTTGGA 30

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

TATGCAAGCT TACTCCTCGT CCTGCAGGTT 30

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60
CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120
GACGAGGAGC TCTGCGGGGG GCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180
CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240
CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCAGCT GTCTTCGCTT CGTCCAGACC 300
AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360
ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 405

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 420 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60
CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120
GACGAGGAGC TCTGCGGGGG CTTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180
CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240
CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCAGCT GTCTTCGCTT CGTCCAGACC 300
AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360
ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCCTG 420

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 366 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60
CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120
GACGAGGAGC TCTGCGGGGG CTTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180
CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240
CACTTTGTCA CCAAATGTGC CTTTCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 300
TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTACAGC CGACTCCTCA 360
ACCCCTG 366

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

GGAAGTCAGG	ATTGTTCTTT	CCAACACAGC	CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	60
CGTGAGCTGT	CTGACTACCT	GCTTCAAGAT	TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG	120
GACGAGGAGC	TCTGCGGGGG	CCTCTGGCGG	CTGGTCCTGG	CACAGCGCTG	GATGGAGCGG	180
CTCAAGACTG	TCGCTGGGTC	CAAGATGCAA	GGCTTGCTGG	AGCGCGTGAA	CACGGAGATA	240
CACCTTGTCA	CCAAATGTGC	CTTTCAGCCC	CCCCCAGCT	GTCTTCGCTT	CGTCCAGACC	300
AACATCTCCC	GCCTCCTGCA	GGAGACCTCC	GAGCAGCTGG	TGGCGCTGAA	GCCCTGGATC	360
ACTCGCCAGA	ACTTCTCCCG	GTGCCTGGAG	CTGCAGTGTC	AGCCC		405

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 420 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

GGTACCCAGG	ATTGTTCTTT	CCAACACAGC	CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	60
CGTGAGCTGT	CTGACTACCT	GCTTCAAGAT	TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG	120
GACGAGGAGC	TCTGCGGGGG	CCTCTGGCGG	CTGGTCCTGG	CACAGCGCTG	GATGGAGCGG	180
CTCAAGACTG	TCGCTGGGTC	CAAGATGCAA	GGCTTGCTGG	AGCGCGTGAA	CACGGAGATA	240
CACCTTGTCA	CCAAATGTGC	CTTTCAGCCC	CCCCCAGCT	GTCTTCGCTT	CGTCCAGACC	300
AACATCTCCC	GCCTCCTGCA	GGAGACCTCC	GAGCAGCTGG	TGGCGCTGAA	GCCCTGGATC	360
ACTCGCCAGA	ACTTCTCCCG	GTGCCTGGAG	CTGCAGTGTC	AGCCCGACTC	CTCAACCTCG	420

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

GCCACTCAGG	ACTGTTCTTT	CCAACACAGC	CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	60
CGTGAGCTGT	CTGACTACCT	GCTTCAAGAT	TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG	120
GACGAGGAGC	TCTGCGGGGG	CCTCTGGCGG	CTGGTCCTGG	CACAGCGCTG	GATGGAGCGG	180
CTCAAGACTG	TCGCTGGGTC	CAAGATGCAA	GGCTTGCTGG	AGCGCGTGAA	CACGGAGATA	240
CACCTTGTCA	CCAAATGTGC	CTTTCAGCCC	CCCCCAGCT	GTCTTCGCTT	CGTCCAGACC	300
AACATCTCCC	GCCTCCTGCA	GGAGACCTCC	GAGCAGCTGG	TGGCGCTGAA	GCCCTGGATC	360
ACTCGCCAGA	ACTTCTCCCG	GTGCCTGGAG	CTGCAGTGTC	AGCCC		405

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 420 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

GCCACTCAGG	ACTGTTCTTT	TCAACACAGC	CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	60
CGTGAGCTGT	CTGACTACCT	GCTTCAAGAT	TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG	120
GACGAGGAGC	TCTGCGGGGG	CCTCTGGCGG	CTGGTCCTGG	CACAGCGCTG	GATGGAGCGG	180
CTCAAGACTG	TCGCTGGGTC	CAAGATGCAA	GGCTTGCTGG	AGCGCGTGAA	CACGGAGATA	240
CACCTTGTCA	CCAAATGTGC	CTTTCAGCCC	CCCCCAGCT	GTCTTCGCTT	CGTCCAGACC	300
AACATCTCCC	GCCTCCTGCA	GGAGACCTCC	GAGCAGCTGG	TGGCGCTGAA	GCCCTGGATC	360
ACTCGCCAGA	ACTTCTCCCG	GTGCCTGGAG	CTGCAGTGTC	AGCCCGACTC	CTCAACCTCG	420

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

```

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG    60
CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG    120
ATACACTTTG TCACCAAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG    180
ACCAACATCT CCGCCTCTCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG    240
ATCACTCGCC AGAAGTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC    300
CTGCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC    360
TCCTTCCAAC ACAGCCCAT CTCCTCCGAC TTGCTGTCA AAATCCGTGA GCTGTCTGAC    420
TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCAACC TGCAG    465

```

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 450 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

```

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG    60
CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG    120
ATACACTTTG TCACCAAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG    180
ACCAACATCT CCGCCTCTCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG    240
ATCACTCGCC AGAAGTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC    300
CTGTCAAGCG GTAACGGCAG TGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC    360
CCCCTCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT    420
TACCCAGTCA CCGTGGCTTC CAACCTGCAG    450

```

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 435 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

```

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG    60
CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG    120
ATACACTTTG TCACCAAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG    180
ACCAACATCT CCGCCTCTCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG    240
ATCACTCGCC AGAAGTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC    300
CTGTCTGCGG GCAACGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCAT CTCCTCCGAC    360
TTGCTGTGTA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG    420
GCCTCAACC TGCAG    435

```

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

```

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAA    60
TGTCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCTCGCTC    120
CTCCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC    180
TCCCGGTGCC TGGAGTGCA GTGTCAGCCC GACTTCCTAA CCCTGTCTGG AGGTAACGGA    240
TCCCGGTGCC ATGGGAGCGG CGGAAATGGA ACCCAGGACT GCTCCTTCCA ACACAGCCCC    300
ATCTCTCCG ACTTCGCTGT CAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC    360
CCAGTCACCG TGGCTTCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG    420

```

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCTG CTGGG

465

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 450 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

GCCTCCAAGA	TGCAAGGCTT	GCTGGAGCGC	GTGAACACGG	AGATACACTT	TGTCACCAAA	60
TGTGCCTTTC	AGCCCCCCCC	CAGCTGTCTT	CGCTTCGTCC	AGACCAACAT	CTCCCGCCTC	120
CTGCAGGAGA	CCTCCGAGCA	GCTGGTGGCG	CTGAAGCCCT	GGATCACTCG	CCAGAACTTC	180
TCCCGGTGCC	TGGAGCTGCA	GTGTACAGCC	GACTCCTCAA	CCCTGTCTGG	AGGTAACGGA	240
TCCGAGGTA	ATGGCACCCA	GGACTGCTCC	TTCCAACACA	GCCCCATCTC	CTCCGACTTC	300
CCTGTCAAAA	TCCGTGAGCT	GTCTGACTAC	CTGCTTCAAG	ATTACCCAGT	CACCGTGGCC	360
TCCAACCTGC	AGGACGAGGA	GCTCTGCGGG	GGCCTCTGGC	GGCTGGTCTT	GGCACAGCGC	420
TGGATGGAGC	GGCTCAAGAC	TGTCGCTGGG				450

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 435 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

GCCTCCAAGA	TGCAAGGCTT	GCTGGAGCGC	GTGAACACGG	AGATACACTT	TGTCACCAAA	60
TGTGCCTTTC	AGCCCCCCCC	CAGCTGTCTT	CGCTTCGTCC	AGACCAACAT	CTCCCGCCTC	120
CTGCAGGAGA	CCTCCGAGCA	GCTGGTGGCG	CTGAAGCCCT	GGATCACTCG	CCAGAACTTC	180
TCCCGGTGCC	TGGAGCTGCA	GTGTACAGCC	GACTCCTCAA	CCCTGTCTGG	CGGCAACGGC	240
ACGCAAGGACT	GCTCCTTCCA	ACACAGCCCC	ATCTCCTCCG	ACTTCGCTGT	CAAAATCCGT	300
GAGCTGTCTG	ACTACCTGCT	TCAAGATTAC	CCAGTCACCG	TGGCTCCAA	CCTGCAGGAC	360
GAGGAGCTCT	GCGGGGCTCT	CTGGCGGCTG	GTCTTGGCAC	AGCGCTGGAT	GGAGCGGCTC	420
AAGACTGTCTG	CTGGG					435

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

GCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	ACCAACATCT	CCCGCCTCCT	GCAGGAGACC	60
TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	120
GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	CTGTCTGGAG	GTAACGGCAG	TGGTGGCAAT	180
GGGAGCGGTG	GAATGGGAAC	CCAGGACTGC	TCCTTCCAAC	ACAGCCCCAT	CTCCTCCGAC	240
TTGCTGTGTA	AAATCCGTGA	GCTGTCTGAC	TACCTGCTTC	AAGATTACCC	AGTCACCGTG	300
GCCTCAACC	TGCAGGACGA	GGAGCTCTGC	GGGGGCTCTT	GGCGGCTGGT	CCTGGCACAG	360
CGCTGGATGG	AGCGGCTCAA	GACTGTCTGCT	GGGTCCAAGA	TGCAAGGCTT	GCTGGAGCGC	420
GTGAACACGG	AGATACACTT	TGTCACCAAA	TGTGCCTTTC	AGCCC		465

(2) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 450 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

GCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	ACCAACATCT	CCCGCCTCCT	GCAGGAGACC	60
TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	120
GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	CTGTACGGCG	GTAACGGCAG	TGGAGGTAAT	180
GGCACCAGG	ACTGTCTCTT	CCAACACAGC	CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	240

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCSTGGCCTC CAACCTGCAG 300
 GACGAGGAGC TCTGCGGGG CCTCTGCGG CTGCTCCTGG CACAGCGCTG GATGGAGCGG 360
 CTCAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 420
 CACTTTGTCA CCAATGTGC CTTCAGCCCC 450

(2) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 435 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GGCCCCCA GCTGTCTCG CTTCCTCCAG ACCAACATCT CCCGCCCTCT GCAGGAGACC 60
 TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120
 GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC 180
 TCCTTCCAAC ACAGCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 240
 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 300
 GGGGGCCTCT GCGCGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCTGCT 360
 GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTACCAAAA 420
 TGTGCCTTTC AGCCC 435

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 451 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60
 CGGCTCAAGA CTGTGCGTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120
 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCCTCCAG 180
 ACCAACATCT CCCGCCCTCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240
 ATCACTCGCC AGAACTTCTC CCGGTGCTTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300
 CTGTCTGGAG GTAGTGGATC CGGAGGTTCT GSCAACCCAG GACTGCTCCT TCCAACACAG 360
 CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTCAAGA 420
 TTACCCAGTC ACCGTGGCCT CCAACCTGCA G 451

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60
 CGGCTCAAGA CTGTGCGTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120
 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCCTCCAG 180
 ACCAACATCT CCCGCCCTCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240
 ATCACTCGCC AGAACTTCTC CCGGTGCTTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300
 CTGTCTGGAG GTAGTGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC CCAGGACTGC 360
 TCCTTCCAAC ACAGCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420
 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 437 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCAT CTCCTCCGAC TTCGCTGTCA 60

AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120
 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GCGGGCTGGT CCTGGCACAG CGCTGGATGG 180
 AGCGGCTCAA GACTGTCTGT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240
 AGATACACTT TGTACCAAAA TGTGCTTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300
 AGACCAACAT CTCCCGCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360
 GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTACAGCC GACTCCTCAA 420
 CCTGGGCGG TGGATCC 437

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 436 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 60
 GTCAAAATCC GTGAGCTGTC TGAATACCTG CTTCAGATT ACCCAGTCAC CGTGGCCTCC 120
 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCTTGGC ACAGCGCTGG 180
 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 240
 ACGGAGATAC ACTTTGTAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 300
 GTCCAGACCA ACATCTCCCG CCTCTGCAG GAGACCTCG AGCAGCTGGT GCGCGTGAAG 360
 CCTGGATCA CTCGCCAGAA CTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCGCGACTCC 420
 TCAACCTGT AAGCTT 436

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 449 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60
 AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120
 TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GCGGGCTGGT CCTGGCACAG CGCTGGATGG 180
 AGCGGCTCAA GACTGTCTGT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240
 AGATACACTT TGTACCAAAA TGTGCTTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300
 AGACCAACAT CTCCCGCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360
 GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTACAGCC GACTCCTCAA 420
 CCTGGGCGG TGGGTCAAGA GGTGGATCC 449

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 439 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCATCTC CTCGACTTC 60
 GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 120
 TCCAACCTGC AGGACGAGGA GCTCTGCGG GGCCTCTGGC GGCTGGTCTT GGCACAGCGC 180
 TGGATGGAGC GGCTCAAGAC TGTGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 240
 AACACGGAGA TACACTTTGT CACCAATGT GCCTTTTACG CCCCCCCCAG CTGCTTTCGC 300
 TTCGTCCAGA CCAACTTCTC CCGCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 360
 AAGCCCTGGA TCACTCGCCA GAACCTTCTC CGGTGCTTG AGCTGCAGTG TCAGCCCGAC 420
 TCCTCAACCC TGTAAGCTT 439

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 461 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

CCATGGCCAC	CCAGGACTGC	TCCTTCCAAC	ACAGCCCCAT	CTCCTCCGAC	TTGCGTGTCA	60
AAATCCGTGA	GCTGTCTGAC	TACCTGCTTC	AAGATTACCC	AGTCACCGTG	GCCTCCAACC	120
TGCAGGACGA	GGAGCTCTGC	GGGGGCTCT	GGCGGCTGGT	CCTGGCACAG	CGCTGGATGG	180
AGCGGCTCAA	GACTGTGCT	GGGTCCAAGA	TGCAAGGCTT	GCTGGAGCGC	GTGAACACGG	240
AGATACACTT	TGTACCAAAA	TGTGCCTTTC	AGCCCCCCCC	CAGCTGTCTT	CGCTTCGTCC	300
AGACCAACAT	CTCCCGCTC	CTGCAGGAGA	CCTCCGAGCA	GCTGGTGGCG	CTGAAGCCCT	360
GGATCACTCG	CCAGAACTTC	TCCCGGTGCC	TGGAGCTGCA	GTGTCAGCCC	GACTCCTCAA	420
CCCTGGGCGG	TGGGTCAAGG	GGTGGGTGAG	GAGGTGGATC	C		461

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 457 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

GGATCCGGAG	GTGGCTCAGG	GGGAGGTAGT	GGTACCCAGG	ACTGCTCCTT	CCAACACAGC	60
CCCATCTCCT	CCGACTTCGC	TGTCAAAATC	CGTGAGCTGT	CTGACTACCT	GCTTCAAGAT	120
TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG	GACGAGGAGC	TCTGCGGGGG	CCTCTGGCGG	180
CTGGTCTCTG	CACAGCGCTG	GATGGAGCGG	CTCAAGACTG	TCGCTGGGTC	CAAGATGCAA	240
GGCTTGCTGG	AGCGCGTGAA	CACGGAGATA	CACTTTGTCA	CCAAATGTGC	CTTTCAGCCC	300
CCCCCAGCT	GTCTTCGCTT	CGTCCAGACC	AACATCTCCC	GCCTCCTGCA	GGAGACCTCC	360
GAGCAGCTGG	TGGCGCTGAA	GCCTTGGATC	ACTCGCCAGA	ACTTCTCCCG	GTGCCTGGAG	420
CTGCAGTGTC	AGCCCGACTC	CTCAACCTTG	TAAGCTT			457

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 438 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTTG	TCACCAAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCTC	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTGAGCCCGA	CTCCTCAACC	300
CTGGGCGGTG	GATCCGGAGG	TACCCAGGAC	TGCTCCTTCC	AACACAGCCC	CATCTCCTCC	360
GACTTCGCTG	TCAAAATCCG	TGAGCTGTCT	GACTACCTGC	TTCAGATTA	CCCRGTCAAC	420
GTGGCTTCCA	ACCTGCAG					438

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTTG	TCACCAAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCTC	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTGAGCCCGA	CTCCTCAACC	300
CTGGGCGGTG	GATCCGGAGG	TGGCAGCCAG	GACTGTCTCT	TCCAACACAG	CCCCATCTCC	360
TCCGACTTCG	CTGTCAAAAT	CCGTGAGCTG	TCTGACTACC	TGCTTCAAGA	TTACCCAGTC	420
ACCGTGGCCT	CCAACCTGCA	G				441

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 450 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTIG	TCACCAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCT	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	300
CTGGGCGGTG	GGTCAGGAGG	TGGATCCGGA	GGTACCCAGG	ACTGCTCCTT	CCAACACAGC	360
CCCCTCTCCT	CCGACTTCGC	TGTCAAAATC	CGTAGCTGTG	CTGACTACCT	GCTTCAAGAT	420
TACCCAGTCA	CCGTGGCCTC	CAACCTGCAG				450

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 459 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTIG	TCACCAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCT	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	300
CTGGGCGGTG	GATCCGGAGG	TGGCTCAGGG	GGAGGTAGTG	GTACCCAGGA	CTGCTCCTTC	360
CAACACAGCC	CCATCTCCTC	CGACTTCGCT	GTCAAAATCC	GTGAGCTGTC	TGACTACCTG	420
CTTCAAGATT	ACCCAGTCAC	CGTGGCCTCC	AACCTGCAG			459

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTIG	TCACCAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCT	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	300
CTGGGCGGTG	GGTCAGGAGG	TGGGTCAAGG	GGTGGATCCG	GAGGTGGCAC	CCAGGACTGC	360
TCCTTCCAAC	ACAGCCCCAT	CTCCTCCGAC	TTGCTGTCA	AAATCCGTGA	GCTGTCTGAC	420
TACCTGCTTC	AAGATTACCC	AGTCACCGTG	GCCTCCAACC	TGCAG		465

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 483 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

GCCGACGAGG	AGCTCTGCGG	GGGCTCTGG	CGGCTGGTCC	TGGCACAGCG	CTGGATGGAG	60
CGGCTCAAGA	CTGTGCTGG	GTCCAAGATG	CAAGGCTTGC	TGGAGCGCGT	GAACACGGAG	120
ATACACTTIG	TCACCAAATG	TGCCTTTCAG	CCCCCCCCCA	GCTGTCTTCG	CTTCGTCCAG	180
ACCAACATCT	CCCGCTCCT	GCAGGAGACC	TCCGAGCAGC	TGGTGGCGCT	GAAGCCCTGG	240
ATCACTCGCC	AGAACTTCTC	CCGGTGCCTG	GAGCTGCAGT	GTCAAGCCGA	CTCCTCAACC	300
CTGGGCGGTG	GGTCAGGAGG	TGGGTCAAGG	GGTGGATCCG	GAGGTGGCTC	AGGGGGAGGT	360
AGTGGTACCC	AGGACTGCTC	CTTCCAACAC	AGCCCCATCT	CCTCCGACTT	CGCTGTCAAA	420
ATCCGTGAGC	TGTCTGACTA	CCTGCTTCAA	GATTACCCAG	TACCCGTGGC	CTCCAACCTG	480
CAG						483

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

```

GCCGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC   60
TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTGCG TGGGTCCAAG   120
ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTACCAA ATGTGCTTTT   180
CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCGCTT CCTGCAGGAG   240
ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCGGGTGC   300
CTGGAGCTGC AGTGTACGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAAG AGTGGGTCA   360
GGAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC   420
GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAA                      465

```

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

```

GCCGCTCCA ACCTGCAGGA CGAGGAGCTC TGGCGGGGCC TCTGGCGGCT GGTCTGGCA   60
CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTGTCTGGAG   120
CGCGTGAACA CGGAGATACA CTTTGTCAAC AAATGTGCTT TTCAGCCCCC CCCCAGCTGT   180
CTTGGCTTCG TCCAGACCAA CATCTCCCGC CTCTGCAGG AGACCTCCGA GCAGCTGGTG   240
GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTGAG   300
CCCAGCTCCT CAACCCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT   360
GGCAGCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC   420
CGTGAGCTGT CTGACTACCT GCTCAAGAT TACCCAGTCA CCGTG                      465

```

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

```

GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT   60
GTCACCAAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC   120
TCCCGCTTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGGCG TGAAGCCCTG GATCACTCCC   180
CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT   240
GGTCAAGGAG GTGGGTGAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA   300
CACAGCCCA TCTCTCCGA CTTCGTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT   360
CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC   420
TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACT                      465

```

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

```

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTACCAAAA   60
TGTGCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCTGCCTC   120
CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC   180
TCCCGGTGCC TGGAGCTGCA GTGTCAAGCC GACTCCTCAA CCTGGGCGG TGGGTCAAGGA   240
GGTGGGTGAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC   300
ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC   360
CCAGTACCCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT CGGGGGGCTT CTGGCGGCTG   420
GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCT CTGGG                      465

```

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

```

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC   60
TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG   120
GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAAGGAG TGGGTCAAGG   180
GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC   240
TTCCCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG   300
GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GCGCGCTGGT CCTGGCACAG   360
CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC   420
GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC               465

```

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

```

GCCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG   60
GCGCTGAAGC COTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTGAG   120
CCCGACTCCT CAACCCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT   180
GGCACCACAG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC   240
CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCTTC CAACCTGCAG   300
GACGAGGAGC TCTGCGGGGG CCTCTGCGGG CTGCTCCTGG CACAGCGCTG GATGGAGCGG   360
CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA   420
CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCAGCT GTCTT              465

```

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

```

GCCACCAACA TCTCCCGCCT CTGCAAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC   60
TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTGAGCC CGACTCCTCA   120
ACCCTGGGCG GTGGGTCAAG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC   180
TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT   240
GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC   300
TGTGGGGGCC TCTGGCGGCT GGTCTGGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC   360
GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTACCC   420
AAATGTGCCT TTCAGCCCCC CCCAGCTGT CTTCGCTTCG TCCAG              465

```

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 134 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

```

Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala
 1           5           10
Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val
          20           25           30

```

```

Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp
  35          40          45
Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala
  50          55          60
Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
  65          70          75          80
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
  85          90          95
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
  100         105         110
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
  115         120         125
Glu Leu Gln Cys Gln Pro
  130

```

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

```

Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala
  1          5          10          15
Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val
  20          25          30
Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp
  35          40          45
Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala
  50          55          60
Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
  65          70          75          80
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
  85          90          95
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
  100         105         110
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
  115         120         125
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu
  130         135

```

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 209 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

```

Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala
  1          5          10          15
Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val
  20          25          30
Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp
  35          40          45
Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala
  50          55          60
Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
  65          70          75          80
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
  85          90          95
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
  100         105         110
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
  115         120         125
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser
  130         135         140
Pro Arg Pro Leu Glu Ala Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu

```

[illegible]

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 402 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

ACCCAGGACT	GCTCCTTCCA	ACACAGCCCC	ATCTCTCTCG	ACTTCGCTGT	CAAAATCCGT	60
GAGCTGTCT	ACTACCTTCT	TCAGATTATC	CCAGTCAACG	TGGCCCTGAA	CTCTCAGGAC	120
GAGAGACTCT	CGGGGGGCGT	CTGGCGGCTC	CTCTTGGAC	AGCCGCTCGAT	GGAGCGGGCT	180
AAGACTGTCTG	CTGGGTCCTA	GATGCAAGCG	TTGCTGGAGC	TCGTGAACAC	GGAGATCAAC	240
TTTGTTCACCA	AATGTGCCAA	TCAGCCCCCC	CCAGCTGTTC	TGCTTCTTCG	CGACATCAAC	300
ATCTTCCCGCC	TCCTTCGAGG	CTGCTCCGAG	CAGCTGGTGG	CGCTGAAGCC	CTGGATCAAT	360
CGCCAGCAAT	TCTTCCGGTG	CTGAGGACTG	CAGTGTGAGC	CC		402

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 630 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

ACCCAGGACT	GCTCCTTCCA	ACACAGCCCC	ATCTCCTCG	ACTTCGCTGT	CAAAATCCGT	60
GAGCTGTGTC	ACTACCTGCT	TCAGAGATTAC	CAGTCAACG	TGGCGCTGAA	CTCTGAGGAC	120
GAGAGAGCTC	CGGGGGGCGT	CTGGCGGATTC	GTCTCCGATC	AGCGCTCGAA	GGAGCGCGCT	180
AAGATCTGTC	CTGGGTCCAA	GATGCAACCG	TTGCTGGAGC	GCGTGAACAC	GGAGATACAC	240
TTGTGCACCA	AATGTGCTTT	TCAGCCCCCC	CCGAGCTGTC	TTCGTTTCGT	CCAGACCAAC	300
ATCTCCCGCC	TCTTCGAGGA	GACCTCCGAG	CAGTGTGGTG	CTCGTGAAGC	CTGTGATCACT	360
CGCCAGACCT	TCCTCCGGGT	CTCTGAGCTG	CAGTGTGACG	CGGACTCCTC	AACCTTGCCA	420
CCCCATCTGGA	GTCGCCCGGC	CTGTGAGGCTC	ACAGCCCCGA	CAGCCCGCGA	GCCCCCTCTG	480
CTCTCTCTACT	TGCTGCTGCC	CTGTGGCGTC	TGCTGCTGG	CCGCTCGCTG	TGCTCTGCAC	540
TGGCAGAGGA	CGCGCTCGGT	GACACCCGCG	CCTGGGGAGC	TAGCTGCCCC	CCTCCCCAGT	600
CCCCAGGACC	TGCTGCTTGT	GAGGACATGA				630

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- 1/ SEQUENCE CHARACTERISTICS
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
20 25

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- 1) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr Ala
1 5 10 15
Gly Gln Pro Pro Leu
20

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Val Glu Thr Val Phe His Arg Val Ser Gln Asp Gly Leu Leu Thr Ser
1 5 10 15

The claims defining the invention are as follows:

1. A human flt-3 receptor agonist polypeptide,
comprising a modified flt-3 ligand amino acid sequence
5 of the Formula:

```

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg
                                10                      20
10  GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp
                                30                      40
    GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu
                                50                      60
15  LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis
                                70                      80
    PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn
20  90                      100
    IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr
                                110                     120
25  ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu
                                130                     SEQ ID NO:144

```

wherein 1-7 are optionally deleted from the C-terminus
of said flt-3 receptor agonist polypeptide of SEQ ID

30 NO:144;

wherein the N-terminus is joined to the C-terminus
directly or through a linker capable of joining the N-
terminus to the C-terminus and having new C- and N-
35 termini at amino acids;

28-29	42-43	93-94
29-30	64-65	94-95
30-31	65-66	95-96
31-32	66-67	96-97
32-33	86-87	97-98
34-35	87-88	98-99
36-37	88-89	99-100
37-38	89-90	100-101
38-39	90-91	101-102
39-40	91-92	102-103
40-41	92-93	respectively; and
41-42		



additionally said new N-terminus of said flt-3 receptor agonist polypeptide can be immediately preceded by (methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).

5

2. The flt-3 receptor agonist polypeptide, as recited in claim 1, wherein said linker is selected from the group consisting of;

- 10 GlyGlyGlySer SEQ ID NO:38;
 GlyGlyGlySerGlyGlyGlySer SEQ ID NO:39;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO:40;
 SerGlyGlySerGlyGlySer SEQ ID NO:41;
 GluPheGlyAsnMet SEQ ID NO:42;
 GluPheGlyGlyAsnMet SEQ ID NO:43;
 15 GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO:44;
 GlyGlySerAspMetAlaGly SEQ ID NO:45;
 SerGlyGlyAsnGly SEQ ID NO:46;
 SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:47;
 SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO:48;
 20 SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:49;
 SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ ID NO:50;
 GlyGlyGlySerGlyGly SEQ ID NO:51;
 GlyGlyGlySerGlyGlyGly SEQ ID NO:52;
 GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:53;
 25 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:54;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO:55;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly
 GlyGlySerGly SEQ ID NO:56;
 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly
 30 GlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:148;
 ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly
 GlnProProLeu SEQ ID NO:149;
 ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO:150;
 and
 35 ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer SEQ ID
 NO:151.



3. The flt-3 receptor agonist polypeptide, as recited in claim 1, selected from the group consisting of;

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu
ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys
SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:8;

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu
ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer
ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp
TyrProValThrValAlaSerAsnLeuGln SEQ ID NO:9;

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu
ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu
IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln
ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp
IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr
LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
AlaSerAsnLeuGln SEQ ID NO:10;

AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro
IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr
ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu
ValLeuAlaGlnArgTrpMETGluArgLeuLysThrValAlaGly SEQ ID NO:11;

AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe
AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla
SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg
TrpMETGluArgLeuLysThrValAlaGly SEQ ID NO:12;



AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
 CysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
 5 LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
 SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly
 ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg
 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp
 10 GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArgLeu
 LysThrValAlaGly SEQ ID NO:13;

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
 SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
 15 GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn
 GlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
 PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
 AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln
 ArgTrpMETGluArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArg
 20 ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:14;

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
 SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
 25 GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn
 GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
 ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
 AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArg
 30 LeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIle
 HisPheValThrLysCysAlaPheGlnPro SEQ ID NO:15;

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
 SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
 35 GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCys
 SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp
 TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys
 GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArgLeuLysThrValAla
 40 GlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
 CysAlaPheGlnPro SEQ ID NO:16;

AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu
 TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys
 45 MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe
 GlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGlu
 ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys
 LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer
 50 GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer
 AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO:31;

AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla
 GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu
 55 ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys
 LeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal



AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln
ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO:32;

5

AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe
ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIle
SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArg
GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly
GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln
HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu
GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu
TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO:33;

15

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys
CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu
LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe
SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly
GlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro
IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr
ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu
ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:34;

25

AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr
SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu
GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly
GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp
PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal
AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln
ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg
ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:35;

35

AlaArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal
AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln
ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly
GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle
ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln
AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg
LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle
HisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO:36;

45

AlaThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro
TrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer
ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp
CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer
AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu
CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal
AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr
LysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO:37.

55



4. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 1.

5

5. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 2.

10

6. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 3.

7. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 6, selected from the group consisting of:

20 GCGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGTGCCTGGAGCTGCAGTGTCAAGCCGACTCCTCAACC
CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC
25 CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG
GCCTCCAACCTGCAG SEQ ID NO:113;

30 GCGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
35 AGAACTTCTCCCGTGCCTGGAGCTGCAGTGTCAAGCCGACTCCTCAACC
CTGTCAAGGCGGTAACGGAGTGGAGGTAATGGCACCCAGGACTGCTCCTT
CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT
CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGCGCTCCAACCTGCAG
SEQ ID NO:114;

40

45 GCGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG
CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCCTTTCAG
CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGTGCCTGGAGCTGCAGTGTCAAGCCGACTCCTCAACC
CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT
CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC



AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:115;

5 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA
10 ATGGGAGCGCGGAAATGGAACCCAGGACTGTCTCTCAACACAGCCCC
ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT
TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT
CGGGGGCTCTGGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTC
AAGACTGTGCTGGG SEQ ID NO:116;

15 GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
20 GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA
ATGGCACCAGGACTGTCTCTCAACACAGCCCCATCTCTCCGACTTC
GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT
CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCTGGC
GGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGG
25 SEQ ID NO:117;

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT
TGTCACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCC
30 AGACCAACATCTCCCGCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG
CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA
GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCAGCAGGACT
GCTCTTCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAAATCCGT
GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA
35 CCTGCAGGACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGTCTGGCAC
AGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGG SEQ ID NO:118;

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
40 AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAAGCCGACTCCTCAACC
CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAATGGAAC
CCAGGACTGTCTCTCAACACAGCCCCATCTCTCCGACTTCGCTGTCA
AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG
GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGT
45 CTTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGA
TGCAAGGCTTGCTGGAGCGGCTGAACACGGAGATACACTTTGTACCAAAA
TGTCCTTTCAGCCC SEQ ID NO:119;

50 GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAAGCCGACTCCTCAACC
CTGTCAAGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGTCTCT
CCAACACAGCCCCATCTCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT
55 CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCTCCAACCTGCAG
GACGAGGAGCTCTGCGGGGGCTCTGGCGGCTGGTCTGGCACAGCGCTG



GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG
AGCGCGTGAACACGGAGATACACTTTGTACCAAATGTGCTTTTCAGCCC
SEQ ID NO:120;

5
GCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCT
GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC
AGAACTTCTCCCGGTGCCGTGGAGCTGCAGTGTACGCCGACTCCTCAACC
10 CTGCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCAT
CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC
AAGATTACCCAGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGC
GGGGGCTCTGGCGGTGGTCTCTGGCACAGCGCTGGATGGAGCGGCTCAA
GACTGTGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCTGAACACGG
15 AGATACACTTTGTACCAAATGTGCTTTTCAGCCC SEQ ID NO:121;

20
CCCGATTACCCAGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGCGGGG
GCCTCTGGCGGTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCG
TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGT
TCTCCCGCTCCTGCAGGAGACTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT
CACTGCGCAGAACTTCTCCCGGTGCTGGAGCTGCAGTGTACGCCGACTCCTCA
ACCTTGGCGGTGGGTGAGGAGGTGGGTGAGGAGGTGGATCCGAGGTGGCACCC
25 AGGACTGCTCTTCCAACACAGCCCATCTCTCCGACTTCGCTGTCAAAATCCG
TGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO:136;

30
GCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCTCTGGCGGTGGTCC
TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTGCTGGGTCCAAGATGCAAGG
CTTGCTGGAGCGCTGAACACGGAGATACACTTTGTACCAAATGTGCTTTTCAG
CCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCTCCTGCAGG
AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC
CCGTGCTTGGAGCTGCAGTGTACGCCGACTCCTCAACCTGGGCGGTGGGTCA
GGAGGTGGGTGAGGAGCTGGATCCGAGGTGGCACCCAGGACTGCTCTTCCAAC
35 ACAGCCCCATCTCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT
GCTTCAAGATTACCCAGTCACCGTG SEQ ID NO:137;

40
GCGCTGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATAC
ACTTTGTACCAAATGTGCTTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCA
GACCAACATCTCCCGCTCCTGCAGGAGACTCCGAGCAGCTGGTGGCGCTGAAG
CCTGGATCACTCGCCAGAACTTCTCCCGGTGCTGGAGCTGCAGTGTACGCCG
ACTCCTCAACCTGGGCGGTGGGTGAGGAGGTGGGTGAGGAGGTGGATCCGAGG
TGGCACCCAGGACTGCTCTTCCAACACAGCCCATCTCTCCGACTTCGCTGTCT
45 AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCT
CCAACCTGCAGGACGAGGAGCTCTGCGGGGCTCTTGGCGGTGGTCTGGCACA
GCGCTGGATGGAGCGCTCAAGACT SEQ ID NO:138;

50
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCTGAACACGGAGATACACTTTGTCA
CCAAATGTGCTTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT
CTCCCGCTCCTGCAGGAGACTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC
ACTCGCCAGAACTTCTCCCGGTGCTGGAGCTGCAGTGTACGCCGACTCCTCAA
CCCTGGGCGGTGGGTGAGGAGGTGGGTGAGGAGGTGGATCCGAGGTGGCACCCA
55 GGACTGCTCTTCCAACACAGCCCATCTCTCCGACTTCGCTGTCAAAATCCGT
GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCTCCAACCTGC



AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCTGGCACAGCGCTGGAT
GGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO:139;

5 GCGCGCGCTCTGCTTTCGCTTCGTCAGACCAACATCTCCCGCTCTGCAGG
AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC
CCGGTGCCTGGAGCTGCAGTGTGAGCCGACTCCTCAACCTGGCGGCTGGGTCA
GGAGTGGGTGAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC
ACAGCCCATCTCCTCCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACCT
10 GCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC
GGGGCCTCTGGCGGCTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTG
TCGCTGGGTCCAAGATGCAAGGCTTGTCTGGAGCCCGTGAACACGGAGATACACTT
TGTCACCAAATGTGCTTTTCAGCCC SEQ ID NO:140;

15 GCGCGCTTCGTCAGACCAACATCTCCCGCTCTGCAGGAGACCTCCGAGCAGC
TGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGCT
GCAGTGTGAGCCGACTCCTCAACCTGGCGGCTGGGTGAGGAGGTGGGTGAGGA
GGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCATCTCCT
20 CCGACTTCGCTGTCAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC
AGTCACCGTGGCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCTCTGGCGG
CTGGTCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCTGCTGGGTCCAAGA
TGCAAGGCTTGTCTGGAGCGCTGAACACGGAGATACACTTTGTACCAAATGTGC
CTTTCAGCCCCCCCCAGCTGTCTT SEQ ID NO:142;

25 GCCACCAACATCTCCCGCTCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA
AGCCCTGGATCACTCGCCAGAACTTCTCCCGTGCCTGGAGCTGCAGTGTGAGCC
CGACTCCTCAACCCCTGGCGGCTGGGTGAGGAGGTGGGTGAGGAGGTGGATCCGGA
30 GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCATCTCCTCCGACTTCGCTG
TCAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC
CTCCAACCTGCAGGACGAGGAGCTCTCGGGGGCTCTGGCGGCTGGTCTGGCA
CAGCGCTGGATGGAGCGGCTCAAGACTGTCTGCTGGGTCCAAGATGCAAGGCTTGC
TGGAGCGGCTGAACACGGAGATACACTTTGTACCAAATGTGCTTTTCAGCCCCC
35 CCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO:143

8. A method of producing a flt3 receptor agonist polypeptide comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with
40 a replicable vector comprising said nucleic acid molecule of claim 4, 5, 6 or 7 in a manner allowing expression of said flt3 receptor agonist polypeptide and recovering said flt3 receptor agonist polypeptide.

45 9. A composition comprising; a polypeptide of claim 1, 2, or 3; and a pharmaceutically acceptable carrier.



10. A composition comprising; a polypeptide of claim 1, 2, or 3; a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; and a pharmaceutically acceptable carrier.

11. The composition according to claim 10 wherein said factor is selected from the group consisting of: GM-CSF, G-CSF, c-mpl ligand, M-CSF, IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3/flk2 ligand, human growth hormone, B-cell growth factor, B-cell differentiation factor, EPO, and eosinophil differentiation factor; IL-3 variants, fusion proteins, G-CSF receptor agonists, c-mpl receptor agonists, IL-3 receptor agonists, multi-functional receptor agonists; and a pharmaceutically acceptable carrier.

12. A method of stimulating the production of hematopoietic cells in a patient, comprising the step of; administering said polypeptide of claim 1, 2, or 3 to said patient.

13. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering the composition of claim 9, 10 or 11 to said patient.

14. A method for selective ex vivo expansion of stem cells, comprising the steps of;

(a) separating hematopoietic cells from other cells;

(b) culturing said separated hematopoietic cells in a culture medium comprising; the polypeptide of

claim 1, 2, or 3; and

(c) harvesting said cultured cells.



15. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

- (a) culturing said hematopoietic cells in a
5 culture medium, comprising; the composition of claim 9, 10 or 11; and
(b) harvesting said cultured cells.

10 16. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

- (a) separating hematopoietic cells from other cells;
(b) culturing said separated hematopoietic cells
15 in a culture medium, comprising; the composition of claim 9, 10 or 11; and
(c) harvesting said cultured cells.

20 17. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

- (a) removing hematopoietic cells from said patient;
(b) culturing said hematopoietic cells in a
25 culture medium, comprising; a polypeptide of claim 1, 2, or 3;
(c) harvesting said cultured cells; and
(d) transplanting said cultured cells into said patient.

30

18. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

- (a) removing hematopoietic cells from said
35 patient;
(b) separating said hematopoietic cells from other cells;



(c) culturing said separated hematopoietic cells
in a culture medium, comprising; a polypeptide of
claim 1, 2, or 3;

(d) harvesting said cultured cells; and

5 (e) transplanting said cultured cells into said
patient.

19. A method for treatment of a patient having a
hematopoietic disorder, comprising the steps of;

10 (a) removing hematopoietic cells from said
patient;

(b) culturing said hematopoietic cells in a
growth medium, comprising; a polypeptide of claim 1,
2, or 3;

15 (c) harvesting said cultured cells; and

(d) transplanting said cultured cells into said
patient.

20 20. A method for treatment of a patient having a
hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said
patient;

25 (b) separating hematopoietic cells from other
cells;

(c) culturing said separated hematopoietic cells
in a growth medium, comprising; the composition of
claim 9, 10 or 11;

(d) harvesting said cultured cells; and

30 (e) transplanting said cultured cells into said
patient.

21. A method of human gene therapy, comprising
the steps of;

35 (a) removing hematopoietic cells from a patient;



(b) culturing said hematopoietic cells in a growth medium, comprising; a polypeptide of claim 1, 2, or 3;

(d) transducing said cultured cells with DNA;

5 (e) harvesting said transduced cells; and

(f) transplanting said transduced cells into said patient.

22. A method of human gene therapy, comprising
10 the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating said hematopoietic cells from other cells;

(c) culturing said separated hematopoietic cells
15 in a growth medium, comprising; a polypeptide of claim 1, 2, or 3;

(d) transducing said cultured cells with DNA;

(e) harvesting said transduced cells; and

(f) transplanting said transduced cells into said
20 patient.

23. A method of human gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

25 (b) separating said hematopoietic cells from other cells;

(c) culturing said separated hematopoietic cells in a growth medium, comprising; the composition of claim 9, 10 or 11;

30 (d) transducing said cultured cells with DNA;

(e) harvesting said transduced cells; and

(f) transplanting said transduced cells into said patient.

35

24. A method of human gene therapy, comprising the steps of;



- (a) removing hematopoietic cells from a patient;
- (b) separating said hematopoietic cells from other cells;
- (c) culturing said separated hematopoietic cells
- 5 in a growth medium, comprising; the composition of claim 9, 10 or 11;
- (d) transducing said cultured cells with DNA;
- (e) harvesting said transduced cells; and
- (f) transplanting said transduced cells into said
- 10 patient.

25. A method for the production of dendritic cells comprising the steps of;

15

a) separating hematopoietic progenitor cells or CD34+ cells from other cells; and

b) culturing said hematopoietic progenitor

20 cells or CD34+ cells in a growth medium, comprising the flt-3 receptor agonists of claim 1, 2, or 3.

26. The method of claim 25, further comprising the step of;

25

c) pulsing said culturing hematopoietic progenitor cells or CD34+ cells with an antigen.

27. The method of claim 25, wherein said growth medium, further comprises; one or more factor selected

30 from the group consisting of; GM-CSF, IL-4, TNF- α , stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

35

28. The method of claim 26, wherein said growth medium, further comprises; one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF- α , stem



cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

5 29. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; administering the flt-3 receptor agonists of claim 1, 2, or 3, to said human.

10 30. The method of claim 29, further comprising; administering one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF- α , stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional
15 receptor agonist.

31. The method of claim 29, further comprising the step of; administering an antigen to said patient.

20 32. The method of claim 30, further comprising the step of; administering an antigen to said patient.

33. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step
25 of;

a) mobilizing dendritic cell progenitors or mature dendritic cells by administering the flt-3 receptor agonists of claim 1, 2, or 3, to said human;

30 b) removing said dendritic cell precursors or mature dendritic cells by a blood draw or pheresis;

c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and

35 d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human.



34. The method of claim 33, further comprising;
administering in step a), one or more factor selected
from the group consisting of; GM-CSF, IL-4, TNF- α , stem
5 cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant,
an IL-3 variant fusion protein, and a multi-functional
receptor agonist.

35. The method of claim 33, further comprising the
10 step of; culturing said dendritic cell precursors or
mature dendritic cells from step b), in a growth medium,
comprising; the flt-3 receptor agonists of claim 1, 2,
or 3.

36. The method of claim 34, further comprising the
15 step of; culturing said dendritic cell precursors or
mature dendritic cells from step b), in a growth medium,
comprising; the flt-3 receptor agonists of claim 1, 2,
or 3.

37. The method of claim 35, wherein said growth
medium, further comprises one or more factor selected
from the group consisting of; GM-CSF, IL-4, TNF- α , stem
20 cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant,
an IL-3 variant fusion protein, and a multi-functional
25 receptor agonist.

38. The method of claim 36, wherein said growth
medium, further comprises one or more factor selected
30 from the group consisting of; GM-CSF, IL-4, TNF- α , stem
cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant,
an IL-3 variant fusion protein, and a multi-functional
receptor agonist.

35



39. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of;

a) removing hematopoietic progenitor cells or
5 CD34+ cells from said human by a blood draw or pheresis;

b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising the flt-3 receptor agonists of claim 1, 2, or 3 to produce
10 dendritic cell precursors or mature dendritic cells;

c) returning said dendritic cell precursors or mature dendritic cells to said human.

15 40. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of;

a) removing hematopoietic progenitor cells or
20 CD34+ cells from said patient by a blood draw or pheresis;

b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising; the
25 flt-3 receptor agonists of claim 1, 2, or 3, to produce dendritic cell precursors or mature dendritic cells;

c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and
30

d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human.

41. The method of claim 39, further comprising the
35 step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing.



42. The method of claim 40, further comprising the step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing.

5 43. The method of claim 39, wherein said growth medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF- α , stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional
10 receptor agonist.

44. The method of claim 40, wherein said growth medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF- α , stem
15 cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

45. The method of claim 41, wherein said growth
20 medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF- α , stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

25 46. The method of claim 42, wherein said growth medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF- α , stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant,
30 an IL-3 variant fusion protein, and a multi-functional receptor agonist.


DATED this 15 day of March 2001

G.D. SEARLE & CO.,
By its Patent Attorneys,
E. F. WELLINGTON & CO.,
By:

Bruce Wellington
(Bruce Wellington)




FIG.1



SUBSTITUTE SHEET (RULE 26)

2 / 10


FIG.2



SUBSTITUTE SHEET (RULE 26)

3 / 1 0

FIG.3



SUBSTITUTE SHEET (RULE 26)


4 / 10

FIG. 4

I. Construct tandemly-duplicated template



II. PCR-amplify tandemly-duplicated template



5 / 10

FIG. 5A -1

```

1  ACCCAGGACTGCTCCTTCCAAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT 60
   -----+-----+-----+-----+-----+-----+
   TGGGTCCCTGACGAGGAAGTTGTGTCCGGGTAGAGGAGGCTGAAGCGACAGTTT TAGGCA

   ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

61  GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTACCCGTGGCCTCCAACCTGCAGGAC 120
   -----+-----+-----+-----+-----+-----+
   CTCGACAGACTGATGGACGAAGTTCTAATGGGTCACTGGCACCCGAGGTTGGACGTCCTG

   GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

121 GAGGAGCTCTGCGGGGGCCCTCTGGCGGCTGGTCTCTGGCACACAGCGCTGGATGGAGCGGCTC 180
   -----+-----+-----+-----+-----+-----+
   CTCCTCGAGACGCCCCCGGAGACCGCCGACCCAGGACCGTGTCCGCGACCTACCTCGCCGAG

   GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

181 AAGACTGTGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC 240
   -----+-----+-----+-----+-----+-----+
   TTCTGACAGCGACCCAGGTTCTACGTTCCGAACGACCTCGCGCACTTGTGCCTCTATGTG

   LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

```

SUBSTITUTE SHEET (RULE 26)

6 / 10

FIG. 5A-2

```

241 TTTGTCACCAAAATGTGCCTTTCAGCCCCCCCCAGCTGTCTTCGCTTCGTCACACCAAC + 300
-----+-----+-----+-----+-----+-----+
AAACAGTGGTTTACACGGAAGTCGGGGGGGGTCGACAGAAAGCGAAGCAGGTCTGGTTG
PheValThrLysCysAlaPheGlnProProSerCysLeuArgPheValGlnThrAsn

301 ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT + 360
-----+-----+-----+-----+-----+-----+
TAGAGGCGGAGGACGTCTCTGGAGGCTCGTCGACCAACCGGACTTCGGGACCTAGTGA
IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr

361 CGCCAGAACTTCTCCCGGTGCTCGAGCTGCAGTGTCAAGCCCGACTCCTCAACCCCTGCCA + 420
-----+-----+-----+-----+-----+-----+
GCGGTCTTGAAGAGGGCCACGGACCTCGACGTACAGTCGGGCTGAGGAGTTGGGACGGT
ArgGlnAsnPheSerArgCysLeuGluLeuCysGlnProAspSerSerThrLeuPro

421 CCCCCATGGAGTCCCCCGCCCCCTGGAGGCCACAGCCCCGACAGCCCCCGACCCCCCTCTG + 480
-----+-----+-----+-----+-----+-----+
GGGGTACCTCAGGGGCCGGGACCTCCGGTGTCTGGGGCTGTCTGGGGCGCTCGGGGGAGAC
ProProTrpSerProArgProLeuGluAlaThrAlaProThrAlaProGlnProProLeu

```

7 / 10

FIG. 5B

```
CTCCTCCTACTGCTGCTGCCCCGTGGGCCCTCCTGCTGCTGGCCCGCTGCCCTGGTGCCTGCAC      540
-----+-----+-----+-----+-----+-----+-----+
GAGGAGGATGACGACGACGCGGCACCCGGAGGACGACGACCGCGGACCGACCGACCGACGCGTG
LeuLeuLeuLeuLeuLeuProValGlyLeuLeuLeuLeuAlaAlaTrpCysLeuHis
TGGCAGAGGACGCGGGGAGGACACCCCGCCCTGGGGAGCAGGTGCCCCCGTCCCCAGT      600
-----+-----+-----+-----+-----+-----+
ACCGTCTCCTGGCGCGCCTCCTGTGGGGCGGACCCCTCGTCCACGGGGGCAGGGGTCA
TrpGlnArgThrArgArgArgThrProArgProGlyGluGlnValProProValProSer
CCCCAGGACCTGCTGCTTGTGGAGCACTGA
-----+-----+-----+-----+ 630
GGGTCTCCTGGACGACGACACACCTCGTGACT
ProGlnAspLeuLeuLeuValGluHisEnd
```

8 / 10

FIG. 6A

```

1  -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
   ACCCAGGACTGCTCCTTCCAACACAGCCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT      60
   TGGTCCCTGACGAGGAAGTTGTGTCGGGTAGAGGAGGCTGAAGCGACAGTTTTAGGCA

   ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

61  -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
   GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCCTCCAACCTGCAGGAC
   CTCGACAGACTGATGGACGAAGTTCTAATGGGTCAGTGGCACCCGGAGGTTGGACGTCCTG

   GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

121 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
   GAGGAGCTCTCGGGGGCCCTCTGGCGGCTGGTCCTGGCACACCGCTGGATGGAGCGGCTC
   CTCCTCGAGACGCCCCCGGAGACCGCGCGACCCAGGACCGTGTCCGGACCTACCTCGCCGAG

   GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

181 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
   AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACCGGAGATACAC
   TTCTGACAGCGACCCAGGTTCTACGTTCCGAACGACCTCGCGCACTTGTGCCTCTATGTG

   LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

```

9 / 10

FIG. 6B

TTTGTACCAAAATGTGCCTTTTCAGCCCCCCCCCAGCTGTCTTGGCTTCGTCCAGACCAAC 300
241 -----+-----+-----+-----+-----+-----+-----+
AAACAGTGGTTTACACGGAAGTCCGGGGGGGTCGACAGAGCGAAGCAGGTCCTGGTTG
PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn
ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT 360
301 -----+-----+-----+-----+-----+-----+-----+
TAGAGGCGGAGGACGTCCTCTGGAGGCTCGTCGACCCACCGGACTTCGGGACCTAGTGA
IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr
CGCCAGAACTTCTCCGGTGCCCTGGAGCTGCAGTGTCAAGCCC 402
361 -----+-----+-----+-----+-----+-----+-----+
GCGGTCTTGAAGAGGGCCACGGACCTCGACCGTCACAGTCGGG
ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro

SUBSTITUTE SHEET (RULE 26)

10 / 10

FIG. 7

